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ABSTRACT
Breast cancer continues to be the leading cause of cancer-related
death in women worldwide. In this dissertation, natural compounds with
anti-breast cancer activities were identified. We investigated the effect of
Salinomycin, a potassium ionophore isolated from Streptomyces albus, on
the survival of three human breast cancer cell lines MCF-7, T47D and
MDA-MB-231. High concentrations of Salinomycin induced a G2 arrest,
down regulation of survivin and triggered apoptosis. Interestingly,
treatments with low concentrations of Salinomycin induced a transient G1
arrest at an earlier time and G2 arrest and senescence, associated with
enlarged cell morphology, at a later time. There was also an upregulation
of p21 protein, an increase in Histone H3 and H4 hyperacetylation and
expression of SA-β-Gal activity. Furthermore, it was found that
Salinomycin was able to potentiate the killing of the MCF-7 and MDA-MB231 cells, by the chemotherapeutic agents, 4-Hydroxytamoxifen and
frondoside A, We also investigated the effect of Origanum majorana, a
culinary herb, ethanolic extract (OME) on the survival, migration, invasion
and tumor growth of the highly proliferative and invasive triple-negative
p53 mutant breast cancer cell line MDA-MB-231. We found that OME
inhibited the viability of MDA-MB-231 breast cancer cells both in vitro and
in vivo. OME was found to elicit anti-breast cancer activity by inducing
mitotic arrest, DNA damage and triggering the extrinsic apoptotic pathway.
Moreover, OME was found to induce down regulation of survivin,
an important therapeutic target against breast cancer.
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OME was also found to inhibit cell migration and invasion, two major
events required for tumor metastasis. Our data are the first to link
senescence and histone modifications to Salinomycin which provides a
new insight to better understand the mechanism of action of Salinomycin,
at least in breast cancer cells. Moreover, our findings provide strong
evidence that O. majorana may be a promising chemopreventive and
therapeutic candidate against cancer especially for highly invasive triple
negative p53 mutant breast cancer; thus validating its use in alternative
medicine.
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الملخص
اليزال سرطان الثدي السبب الرئيسي للوفيات المرتبطة بالسرطان بين النساء في جميع أنحاء
العالم  .في هذه األطروحة  ،تم دراسة تأثير نشاط بعض المركبات الطبيعية المضادة لسرطان الثدي .في هذه
األطروحة تم دراسة تأثير السالينوميسين  ،مركب حامل أليون البوتاسيوم و الممعزول من الساللة

 ، Streptomuces albusعلى حيوية و تكاثر ثالثة أنواعمن الخاليا البشرية لسرطان الثديMCF :
 T47D ،-7و . MDA- MB- 231أظهرت نتائج البحث أن التركيزات العالية من السالينوميسين أدى إلى

وقف دورة حياة الخاليا عند مرحلة ال  ، G2وانخفاض تنظيم بروتين ال  survivinو تسبب في تحفيز
موت الخاليا المبرمج .ومن المثير لالهتمام أن المعاملة مع تركيزات منخفضة من السالينوميسين نتج عنه توقف

دورة حياة الخاليا عند مرحلة ال G1في خالل  42ساعة من المعالجة و وقف دورة حياة الخاليا في مرحلة
ال  G2و الشيخوخة المرتبطة بكبر في حجم الخاليا في خالل  24ساعة من المعالجة  ،زيادة في تنظيم
البروتين  ، P21وزيادة في هيستون  )hyperacetylation( H3 H4و زيادة في نشاط تعبير من
 .-SA- β-Galعالوة على ذلك  ،وجدنا أن السالينوميسين كان قادرا على تحفيز قتل خاليا الثدي السرطانية

 MCF- 7و  ، MDA- MB- 231عند اإلستخدام مع أدوية العالج الكيميائي4- ،
 Hydroxytamoxifenو  ،frondoside Aعلى التوالي .في الجزء الثاني من األاطروحة تم دراسة
تأثير مستخلص أوراق نبتة البرقوش ) ، (Origanum majoranaو هي نبتة منتشرة في كافة أنحاء
العالم و تستخدم في الطهي و كدواء عشبي تقليدي  ،على حيوية ,تكاثر ,هجرة والغزو و نمو الورم من
خاليا سرطان الثدي واسع ااإلنتشار /الثالثي السلبي ) . (MDA- MB- 231أظهرت نتائج البحث أن
نبتة البردقوش تحول دون جدوى على تكاثر و حيوية خاليا الثدي السرطانية  MDA- MB- 231على
حد سواء في المختبر و نمو الورم في الجسم الحي (الحيوانات المخبرية) .أظهرت النتائج المخبرية أن
نبتة البردقوش تقوم بنشاطها المضاد لسرطان الثدي عن طريق حفز وقف دورة حياة الخاليا اإلنقسامية ،
تحفيز تلف الحمض النووي ( )DNAو التسبب في الموت المبرمج للخاليا عن طريق المسار الخارجي
للموت المبرمج للخاليا .عالوة على ذلك ،أظهرت النتائج أيضا أن مستخلص هذه النبة تحث على تقليل من
تنظيم بروتين ال  ، survivinهدفا عالجيا هاما ضد سرطان الثدي .كذلك وجدنا ان هذا المستخلص فعال في
منع هجرة الخاليا السرطانية و غزوها ألماكن أخرى في الجسم  ،اثنين من األحداث الكبرى األساسية لل ورم

الخبيث.
vi

تقدم النتائج التي توصلنا إليها أدلة قوية على أن مستخلص نبتة البرقوش قد تكون وقائية كيميائية واعدة

و مرشح العالجية ضد السرطان وخاصة بالنسبة لخط خالياسرطان الثدي ثالثي السلبية متحولة البروتين p53
الغازية للغاية ؛ وبالتالي التحقق من صحة استخدامه الطبية التكميلية والبديلة  .األهم من ذلك ،البيانات
المتوفرة لدينا هي األولى التي تربط بين السالينوميسين الشيخوخة و التغير في تعبير الهيستون و الذي
يوفر رؤية جديدة لفهم أفضل آللية عمل السالينوميسين  ،على األقل على خاليا سرطان الثدي.
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CHAPTER 1: INTRODUCTION
1.1 Breast Cancer
Breast cancer is the leading cause of cancer-related death in
women worldwide. Approximately one-third of all women with breast
cancer develop metastasis and ultimately die as a result of the effects of
the disease. The American cancer society estimated nearly 232,670 new
cases and about 40,000 deaths estimated due to breast cancer in women
in 2014 [1]. According to the UAE Ministry of Health, breast cancer is the
most common malignancy diagnosed among women in the UAE. Women
in the UAE tend to develop breast cancer at least a decade earlier than
their counterparts in the West, according to a study [210]. Remarkable
progress has been made in the treatment of breast cancer over the years
with hormonal therapy for estrogen receptors and/or progesterone
receptors positive tumors, as well as other therapies. However, despite
these advances, breast cancer remains a frequent cause of death in
women.
1.2 Tripe Negative Breast Cancer
Triple-Negative Breast Cancer (TNBC) is a subtype of breast
cancer characterized by tumors that do not express estrogen receptors
(ER), progesterone receptors (PR), or human epidermal growth factor
membrane receptors (HER-2). It comprises about 15% of all breast cancer
cases [2]. It is characterized by its unique molecular profile, aggressive
behavior, and distinct pattern of metastasis, including lung, liver and brain
metastasis [3]. Epidemiological studies showed a high prevalence of triple
negative breast cancer among younger women and those of African
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descent. TNBC has a poor prognosis and relapse quickly compared with
other subtypes of breast cancer that are positive for hormonal receptors or
HER2 membrane receptors [4].
Gene-expression profiling approaches demonstrated that TNBC is
a heterogeneous group of diseases composed of different, molecularly
distinct subtypes [4, 5]. Although not synonymous, the majority of TNBC
share morphological and genetic abnormalities with basal-like breast
cancer, a subgroup of breast cancer defined by gene-expression profiling,
where TNBC constitutes approximately 80% of all basal-like tumors.
However, several studies have shown that TNBC includes tumors with a
non-basal expression profile and, in particular, normal-breast, the multiple
markers negative, as well as the recently identified claudin-negative
subtype [4, 5]. TNBC also has molecular features that overlap with breast
cancer, BRCA-1 germline mutation, and is also associated with p53
mutations [2, 6].
TNBC represents an important clinical challenge because these
types of cancer do not respond to hormonal therapy or other available
treatments. Despite advances in the treatment of hormone receptors (HR)
and human epidermal growth factor receptors (HER2)-positive breast
cancers, the prospects for women with TNBC remains poor and
conventional chemotherapy remains the main treatment of TNBC even
though TNBC becomes highly resistant [7]. Preclinical and clinical studies
have suggested several agents that are active in TNBC. These agents
include DNA-damaging agents and poly (ADP-ribose) polymerase (PARP)
inhibitors which are active in TNBC associated with BRCA1 dysfunction.
4

Anti-epidermal growth factor receptors (EGFR) antibodies and EGFR
tyrosine kinase inhibitors are active in TNBC with EGFR gene
amplification. Dasatinib is active in TNBC with activated Src tyrosine
kinase and inhibitors of mammalian target of rapamycin (mTOR) are
active in TNBC with loss of PTEN tumor suppressors. Anti-angiogenic
therapies were shown to enhance antitumor activity of chemotherapeutic
agents in hypervascular TNBC. To develop novel strategies against
TNBC, it is essential to understand the pathways driving the aggressive
behavior of these types of cancer [8-10].
1.3. Cancer Metastasis
Cancer metastasis starts in the primary tumor site when cancer
cells start to invade and degrade the basement membrane and
extracellular matrix (ECM) to get into the vascular or lymphatic circulation
system. Loss of cell to cell adhesion, induces the disassembly of cancer
cells from the primary tumor, disseminating to distant sites through blood
vessels and lymphatics, and eventually they leave the circulation to
establish metastasis in distant organs [11, 12]. E-cadherin, a cell–cell
adhesion molecule, plays a major role in the establishment and
maintenance of normal tissue architecture. It is expressed predominantly
on the surface of normal epithelial cells. For cancer cells to become
metastatic, they must decrease E-cadherin expression and break cell-cell
adhesions and induce cell mobility triggering a transition from tumorigenic
(epithelial) to migratory/invasive (mesenchymal) phenotype ending in
tumor metastasis. Hence, the expression level of the epithelial cadherin
(E-cadherin) has become an important indicator of these transitions [13,
3

14]. Therefore, searching for agents that could enhance E-cadherin
expression is therapeutic aim in order to repress the metastatic potential
of cancer cells.
The adherence of tumor cells to endothelial cells is an essential
step during cancer progression and metastasis. Several adhesive
molecules, such as intracellular adhesion molecule-1 (ICAM-1), have
been identified as being responsible for the endothelial adhesion of cancer
cells [15]. While ICAM-1 expression was found at low basal levels in many
cell types, including epithelial and endothelial cells [16], its expression as
a soluble serum ICAM-1 were found to be high in metastatic breast cancer
patients [16]. Therefore, agents that repress ICAM-1 expression in breast
cancer cells, and subsequently block the interaction between cancer and
endothelial cells, might be an important therapeutic target for repressing
the metastatic potential of cancer cells.
1.3.1. Tumor Cell Invasion in Cancer Metastasis
Degradation of the extracellular matrix (ECM) surrounding the
primary tumor is an essential step in tumorigenesis. This degradation is
important for tissue remodeling and the induction of angiogenesis, and is
mainly mediated by specific proteolytic enzyme systems mainly matrix
metalloproteinase (MMPs) and urokinase plasminogen activator (uPA).
Among MMPs, upregulation of MMP-2 and MMP-9 was shown to be
associated with breast cancer metastasis and poor clinical outcomes [17].
Northern blot analysis revealed that the level of MMP-2 and MMP-9
mRNA was higher in breast cancer tissues compared to normal breast
2

tissue [18]. In addition, higher MMP-9 protein concentration was detected
in breast cancer tissue when compared to normal breast tissue [19].
Similarly, higher protease activity for MMP-2 and MMP-9 was detected by
zymography in tumor tissues compared to normal tissues [20].
MMPs are directly activated by Serine Protease Plasmin, which is
activated from its proenzyme form (plasminogen) by serine protease
urokinase-type plasminogen activator (uPA) upon binding to cell surface
receptors (uPAR). Overexpression of uPA has been found in many tumor
types and is correlated to a poor prognosis. Moreover, binding of uPA to
uPAR also induces signal transduction, allowing enhanced cell migration
[17, 21, 22]. Therefore, regulating the expression of ECM degradation
enzymes is another therapeutic target to control breast cancer.
1.3.2. Angiogenesis in Cancer Metastasis
Angiogenesis is a complex multistep process involving soluble
factors, adhesion molecules, proteases and cytokines. The process of
tumor angiogenesis starts when tumor cells secrete and activate
angiogenic factors, thereby activating proteolytic enzymes. At this time,
endothelial cells proliferate, migrate, and differentiate.
Vascular endothelial growth factor (VEGF) is the most prominent
mediator in tumor angiogenesis that is induced in breast cancer [23]. Upregulation of VEGF expression has been reported in a variety of malignant
human cancers including breast, colon, and lung cancers. An in situ
hybridization study of human breast samples showed high VEGF
expression in tumor cells but not in the normal duct epithelium [24].
2

Hence, VEGF might be a good target in the treatment of breast cancer
patients.
1.3.3. Nuclear Factor B (NFB) in Cancer Progression and
Metastasis
Nuclear Factor B (NFB), (a transcription factor), is a key player in
cancer metastasis [11]. It has been shown that several genes involved in
tumor metastasis are directly regulated by NFB. The frequent overexpression of NFB in tumor cells suggests that selected tumor cells may
acquire metastatic activity via aberrant expression of metastasis relevant
genes during their progression. In fact, studies showed that MMP-2 and
MMP-9 [25, 26], uPA [27, 28], uPAR [29] and ICAM-1 [30] are
downstream targets of the NFB signaling pathway. NF-κB provides
mechanistic links between inflammation and cancer, and moreover,
regulates tumor angiogenesis and invasiveness, indicating that signaling
pathways that mediate their activation provide attractive targets for new
chemotherapeutic approaches [11].

1.4. Programmed Cell Death through Apoptosis
Apoptosis, a major form of programmed cell death, is a defense
mechanism and a tumor suppressor pathway essential for

the

development and maintenance of cellular homeostasis. When deregulated
apoptosis leads to an uncontrolled proliferation of damaged cells. It also
leads to resistance to chemo and radio therapy [31]. Apoptosis can be
triggered by diverse cellular signals. These include intracellular signals
produced in response to cellular stress, such as increased intracellular
5

Ca2+ concentration, DNA damage and high levels of reactive oxygen
species (ROS). Extrinsic inducers of apoptosis include bacterial
pathogens, toxins, nitric oxide, growth factors and hormones [32].
Apoptosis is regulated by a series of signaling cascades and occurs via
two connected pathways. The extrinsic pathway is initiated by cell surface
death receptor stimulation and activation of caspase-8, while the intrinsic
pathway

involves

cytochrome

c

release

from

mitochondria

and

subsequent caspase-9 activation. Activated caspase-8 and-9 activate
executioner caspases, including caspase-3, which in turn activate a
cytoplasmic endonucleases and proteases that degrades nuclear
materials and nuclear and cytoskeletal proteins, respectively, resulting in
elimination of abnormal cells [33]. Evasion from apoptosis is a hallmark of
cancer cells leading to an uncontrolled proliferation of damaged cells and
contributing to cancer development that enhances resistance to
conventional anti-cancer therapies, such as radiation and cytotoxic
therapies. Most chemotherapeutic agents induce cancer cell death by the
activation

of

the

apoptotic

pathway.

However,

most

current

chemotherapeutic drugs are associated with cytotoxic side-effects and the
development of chemo-resistance [34, 35].
1.5. Cell Cycle Control
The cell cycle is series of integrated events controlled by a complex
series of cellular and molecular signaling pathways by which a cell grows,
replicates its DNA and divides. This process also includes mechanisms to
ensure the fidelity of genetic material and corrects errors through
checkpoints; if not, the cells commit suicide (apoptosis) [36, 37].
4

The cell cycle consists of four phases (G1, S, G2 and M). It
governs the transition from quiescence (G0) to cell proliferation. As a cell
approaches the end of the G1 phase, it is controlled at a checkpoint,
called G1/S, where the cell determines whether or not to replicate its DNA.
At this checkpoint the cell is checked for DNA damage to ensure that it
has all the necessary cellular machinery to allow for successful cell
division. As a result of this checkpoint, which involves the interaction of
various proteins, a molecular switch is switched on or off. Cells with intact
DNA continue to S phase while cells with damaged DNA are arrested and
commit suicide through apoptosis, or programmed cell death. A second
such checkpoint occurs at the G2 phase following the synthesis of DNA in
S phase but before cell division in M phase [38, 39].
In eukaryotes, regulation of the cell cycle is controlled, in part, by a
family of protein kinase complexes, and each complex is composed
minimally of a catalytic subunit, the Cyclin Dependent Kinases (CDKs), a
specific enzyme family that uses signals to switch on cell cycle
mechanisms. At least nine structurally related CDKs (CDK1- CDK9) have
been identified. CDKs themselves are activated by forming complexes
with an essential activating partner, cyclin, and another group of
regulatory proteins that are only present for short periods in the cell cycle.
These complexes are activated at specific intervals during the cell cycle
by phosphorylation at specific sites on the CDK by CDK-activating kinase
(CAK), but can also be induced and regulated by exogenous factors.
During the progression of the cell cycle, the cyclin-CDK complexes are
subject to inhibition through binding with a class of proteins known as
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Cyclin Dependent Kinase Inhibitors (CDKIs), such as the CIP/KIP and
INK4 families of proteins [37, 40-42].
In mammalian cells CDKIs are grouped into two classes: (1) p21
(Cip1/Waf1/Cap20/Sdi1/Pic1), p27 (Kip1), and p57 (Kip2) are related
proteins with a preference for Cdk2-and Cdk4-cyclin complexes, (2) also
p16lnk4a, p15lnk4b, p18lnk4c, and p191nk4d are closely related CDKIs
specific for Cdk4- and Cdk6-cyclin complexes [43]. For instance, following
stress signals or DNA damage, p21 and p27 bind to cyclin-CDK
complexes to inhibit their catalytic activity, stop the cell from proceeding to
the next phase of the cell cycle and induce cell-cycle arrest at different
phases [44].
A considerable number of cyclins have been identified (cyclin A–
cyclin T). The pattern of cyclin expression varies with a cell’s progression
through the cell cycle, and this specific cyclin expression pattern defines
the relative position of the cell within the cell cycle [45]. Cyclin D interacts
with CDK2, -4, and -6 and drives cell progression through G1. The
association of cyclin E with CDK2 is active at the G1/S transition and
directs entry into S phase. S phase progression is directed by the cyclin
A/CDK2 complex, and the complex of cyclin A with CDK1 is important in
G2. CDK1/cyclin B is necessary for mitosis to occur [40, 46].
When functioning properly, cell cycle regulatory proteins act as the
body's own tumor suppressors by controlling cell growth and inducing the
death of damaged cells [40]. However, any genetic mutations that cause
the malfunction or absence of one or more of the regulatory proteins at
cell cycle checkpoints can result in a molecular switch being turned
2

permanently on, permitting uncontrolled multiplication of the cell, leading
to carcinogenesis, or tumor development [38].
1.6. Cell Cycle Control and Cancer
A dysregulation of the cell cycle is a hallmark of cancer in which,
contrary to normal cells, tumor cells undergo unrestricted growth without
stopping at predetermined points in the cell cycle. This is due to the
inactivation of critical CDKIs, or to overexpression of cyclins. For instance,
overexpression of cyclin D1 has been associated with the development
and progression of breast cancer [37, 47]. Thus, abrogation of cell cycle
checkpoints through targeting CDKs, CDKIs and/or cyclins would
recapitulate cell cycle checkpoints that limit a tumor cell’s ability to cycle,
and this may induce an apoptotic cascade leading to cell death [48].
Recent studies have suggested that cell cycle arrest in malignant cells is
often associated with apoptotic cell death. In recent years, many studies
have shown the involvement of cell cycle regulation-mediated apoptosis
as a mechanism of cell growth inhibition [59-51] and such targeted
therapy against cancer has become important as an ideal compound for
the management of cancer. In clinical trials a series of targeted agents
directly abrogate the cell cycle checkpoints at critical times and induce
growth arrest to ultimately make the tumor cell susceptible to apoptosis
[52, 53]. Examples of such agents include synthetic cell cycle inhibitors
such as flavopiridol, olomoucine, roscovitine and puvalanol B which are
considered to be a new generation of anticancer drugs [41, 54].
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Interestingly, a number of natural compounds exerted their anticancer activities through the induction of cell cycle arrest at different
phases, which is considered as a promising chemopreventive and
chemotherapeutic strategy, using more efficient and less toxic agents.
Examples of some naturally occurring compounds that have induced cell
cycle arrest, include capsaicin (chili peppers ), kaemopferol (broccoli and
tea), apigenin (parsley and celery), tangeretin (citrus peels), catechins
(tea), cyaniding (cherries and strawberries), 6-gingerol (ginger) and
resveratrol (grapes and red wine) [55- 57].

1.7. Cell Senescence

Cell senescence is a stable cell cycle arrest that occurs in normal
cells after a limited number of cell divisions. However, it is now broadly
defined as a physiological program of terminal growth arrest [58]. It can be
triggered by genetic manipulations or by different forms of stress such as
treatment with chemotherapeutic drugs, radiation or differentiating agents
[59]. Cells that undergo senescence do not proliferate even under mitogen
stimulation, they remain viable and metabolically active but are
permanently growth-arrested and produce secreted proteins such as ECM
components that affect the growth of their neighboring cells (with both
tumor-suppressing and tumor-promoting activities) as well as tissue
organization. Even if not all of the tumor cells are rendered senescent as a
result of an inducing agent (i.e. treatment), such cells may provide a
reservoir of tumor-suppressing factors that will inhibit the growth of nonsenescent cells [60]. Growth arrest is achieved and maintained in either
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the G1 or G2/M stage of the cell cycle, in part, by increased expression of
specific cyclin-dependent kinase inhibitors (CDKIs), including p16Ink4a,
p21Waf1 and p27Kip1 [61].
Senescent cells develop distinct and recognizable flattened and
enlarged cell morphology with a prominent nucleus and increased
cytoplasmic granularity. Most notably, these cells can be visualized with a
staining technique that is a widely accepted and used as a marker,
senescence-associated β-galactosidase (SA-β-gal) activity, which is
detectable by X-gal staining at pH 6.0, reflecting an increased lysosomal
mass of senescent cells, and stains the perinuclear compartment blue
[62].
1.8. Senescence in Cancer Therapy
Cancer therapy has traditionally been based on drug cytotoxicity
that aims to complete the destruction of tumor cells to improve patient
survival. This involves treatment with a high dose of toxic compounds or/
radiation. These approaches may produce complete cell death within a
tumor, however, they have been found to cause severe side effects in
patients and often develop drug resistance and relapse or progress to
advanced primary and metastatic tumors [60]. An alternative strategy is
the induction of senescence, which permanently stop the proliferative
capacity of cells without inducing cancer cell death (cytostatic therapy). It
is of clinical interest that cancerous cells can be induced to a senescent
state in vitro and in vivo with specific conventional anticancer treatments.
The induction of senescence in cancerous cells can sensitize cancerous
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cells more to chemotherapy or radiation but by using lower doses. A
senescence-induced response to chemotherapy has seen found to be
induced by a wide variety of anticancer agents under conditions of
minimal

cytotoxicity.

Recently,

clinical

studies

utilizing

cytostatic

treatments have shown promising preliminary results where therapy
induced senescence has been identified in tumors after radiation or
chemotherapy [63-65]. Although senescence occurs only in a subset of
treated cells, suggesting that these treatments may be as effective as
cytotoxic therapies in inducing permanent growth inhibitory response in
both early and late stage cancers, limiting tumor progression and
providing equivalent or prolonged survival with reduced toxicity related
side effects. Moreover, evidence suggests that therapy inducing
senescence may function as a back-up response to therapy in cancer
cells in which apoptotic pathways are disabled [66]. Therefore, activating
senescence in tumor cells is another attractive approach to cancer
treatment.
Senescence is not the only anti-proliferative response that
determines treatment responses in the absence of apoptosis. Another
principal mechanism for anticancer agents is mitotic catastrophe; cell
death resulting from abnormal mitosis; which usually ends in the formation
of large cells with multiple micronuclei and uncondensed chromatin [67].
Etoposide-induced mitotic catastrophe in HeLa cells was greatly increased
when apoptosis was inhibited by BCL-2 [68]. Also, both mitotic
catastrophe and senescence were shown to be induced in irradiated
tumor cells when apoptotic responses were suppressed [69].
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1.9. Natural Sources As Potential Anti-Cancer Agents

Among the potential alternatives for treating cancer are anti-cancer
agents from natural sources such as plants and dietary phytochemicals,
marine organisms and microorganisms. Throughout history, nature has
been an attractive and rich source of new therapeutic compounds that
have found many applications in cancer therapy, as a tremendous
chemical diversity can be found in millions of species of plants, animals,
marine organisms and microorganisms [70]. Over 70% of all anti-cancer
compounds are either natural products, or natural product-derived
substances or their derivatives (chemically-altered products) that were
developed on the basis of knowledge gained from small molecules or
macromolecules that exist in nature [71]. Chemoprevention and
chemotherapy by naturally occurring agents is now considered to be more
effective, and they do not have large side-effect consequences compared
to synthetic drugs. It is an inexpensive, readily applicable, acceptable and
accessible approach to cancer prevention and treatment [72].
Recent studies have shown that compounds isolated from natural
sources have cytotoxic effects on several types of cancer cells, like
breast, colon, melanoma, uterine, lung and leukemia cells. Moreover,
studies suggest that the consumption of food rich in fruit, vegetables and
spices results in a lower incidence of cancers (stomach, oesophagus,
lung, oral cavity and pharynx, endometrium, pancreas and colon) [56, 70,
71].
Between 2001 and 2005, four new drugs derived from natural
products were approved as anti-cancer agents. The approved anti-cancer
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agents doxorubicin, estradiol in 2002, cholorophyll and l-aspartic acid in
2004 and taxol nanoparticles in 2005 [73]. The marine alkaloid
trabectedin, epothilone derivative ixabepilone and temsirolimus are three
new drugs introduced in 2007 that originated from microbial sources for
the treatment of cancer [74].
1.9.1. Phytochemicals: Dietary Source of Anti-Cancer Agents
Phytochemicals are natural plant-derived compounds that have
been shown to influence human health in many ways. Plants have been a
rich source of highly effective phytochemicals which offer great potential in
the fight against cancer. More than 1,000 different phytochemicals have
already been prove to possess interesting chemo-preventing activities.
Phytochemical are becoming more attractive for cancer prevention and
treatment because they were proven to be very effective, and do not have
serious side-effects compared to synthetic drugs and most importantly,
they can act on specific and/or multiple molecular and cellular targets.
Recently, these natural compounds have become of increasing interest
thanks to their health promoting properties, especially with regard to
breast cancer treatment and prevention [71, 75].
Identification and development of new chemotherapeutic agents
from plants have been recognized in cancer therapy, and have become
major areas for experimental cancer research. Various phytochemicals
present in the diet were found to (i) kill breast cancer cells in vitro and (ii)
prevent and/or suppress breast cancer progression in various preclinical
animal models [76]. Phytochemicals have been shown to target breast
cancer

development

and

progression
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through

inhibiting

cellular

proliferation, suppressing inflammatory processes, arresting cell cycles,
inducing apoptosis, modulating gene expression such as upregulation of
cytoprotective genes that encode for carcinogen detoxifying enzymes and
antioxidant enzymes and/or upregulation of tumor suppressing genes that
encode for tumor suppressor proteins that play an important roles in
cellular signaling pathways, and inhibiting angiogenesis and invasion
potential of many metastatic cancer cell line [77].
Thus, cell signaling cascades and their interacting factors have
become important targets of chemoprevention and chemotherapy in which
phytochemicals and plant based agents seem to be effective. The
mechanistic insight into chemoprevention further includes induction of cell
cycle arrest and apoptosis, or inhibition of signal transduction pathways,
mainly the mitogen-activated protein kinases (MAPK), protein kinases C
(PKC), phosphoinositide 3-kinase (PI3K), glycogen synthase kinase
(GSK) which lead to abnormal cyclooxygenase-2 (COX-2), activator
protein-1 (AP-1), NF-κB and c-Myc expression. The effectiveness of
chemopreventive agents reflects their ability to counteract certain
upstream signals that lead to genotoxic damage, redox imbalances and
other forms of cellular stress [77].
Bioactive natural compounds and the modulated molecular targets
identified through extensive research can be the basis for how these anticancer agents can potentially be used for the prevention and treatment of
cancer. However, a lack of success with targeted monotherapy, resulting
from evading mechanisms, has forced researchers to employ either
combination therapy or agents that interfere with multiple cell-signaling
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pathways. Numerous anti-cancer agents and phytochemicals identified
from plants can interfere with cell-signaling pathways. Examples of
anticancer drugs derived from plants and currently in clinical use include
the vinca alkaloids (vinblastine and vincristine) isolated from Catharanthus
roseus. The Vinca alkaloid was responsible for an increase in the cure
rates of some forms of leukemia [78]. Vincristine was shown to inhibit
microtubule assembly, inducing tubulin self-association into coiled spiral
aggregates [78]. Etoposide is an epipodophyllotoxin, derived from the
mandrake plant Podophyllum peltatum and the wild chervil Podophyllum
emodi [79] and displayed significant promise against small-cell lung
carcinomas [80]. Etoposide is a topoisomerase II inhibitor, stabilizing
enzyme–DNA cleavable complexes leading to DNA breaks [81]. The
taxanes paclitaxel and docetaxel show antitumor activity against breast,
ovarian and other types of tumor in clinical trials. Paclitaxel stabilizes
microtubules leading to mitotic arrest [82]. In addition, the camptothecin
derivatives irinotecan and topotecan, have shown significant antitumor
activity against colorectal and ovarian cancer, respectively [83, 84]. These
later compounds were initially obtained from the bark and wood of
Nyssacea Camptotheca accuminata and act by inhibiting topoisomerase
[85]. The taxanes and the camptothecins are approved for human use in
various countries.
Synthetic flavone, a cyclin-dependent kinase inhibitor, derived from
rohitukine, is a plant alkaloid isolated from the leaves and stems of
Dysoxylum binectariferum [86, 87]. Flavopiridol represents the first cyclindependent kinase inhibitor to enter clinical trials [88]. Its mechanism
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involves interfering with the phosphorylation of cyclin-dependent kinases
and arresting cell-cycle progression at the growth phases G1 or G2 [89,
90].
Homoharringtonine,

another

alkaloid

isolated

from

the

Cephalotaxus harringtonia tree, is efficient against various forms leukemia
[91, 92]. Its mechanism involves the inhibition of protein synthesis and
blocking cell-cycle progression [93]. DNA topoisomerase I inhibitor βlapachone, originally obtained from the Lapacho tree, induces cell-cycle
delay at the G1 or S phase before inducing either apoptotic or necrotic cell
death in a variety of human carcinoma cells, including ovaries, colon,
lungs, prostate and breast [94]. Moreover, there are many plants which
are known to suppress cancers that need further studies to validate their
potential anticancer activities. Examples include Salvia officinalis, Viscum
album, Broussonetia papyrifera, Euphorbia heterophylla, and Viscum
calcaratum. About 117 plants were reviewed in ref. [70] for their anticancer activity.

1.9.1.1. Origanum majorana

Origanum majorana belongs to the family Lamiaceae. It is
commonly known as marjoram. It is a perennial herb and widespread
worldwide. A large number of known species of the genus Origanum are
utilized worldwide as spices and flavoring agents and have a long history
of both culinary and medicinal use. O. majorana is used as a home
remedy for chest infections, coughs, sore throats, rheumatic pains,
nervous disorders, stomach disorders, cardiovascular disease and skin
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care [95, 96]. Many such traditional uses of the marjoram species were
confirmed in several studies utilizing both in vitro and in vivo approaches.

Several reports indicate that O. majorana is very rich in phenolic
compounds. The high phenolic content in Origanum has a capacity to
scavenge free radicals to be associated with strong antioxidant activity
[97]. O. majorana contains phenolic terpenoids (thymol and carvacrol),
flavonoids (diosmetin, luteolin, and apigenin), tannins, hydroquinone,
phenolic glycosides (arbutin, methyl arbutin, vitexin, orientin, and
thymonin) and triterpenoids (ursolic acid and oleanolic acid) [98].

O. majorana has been reported to exhibit significant anti-microbial
activity [99]. Several studies have also demonstrated that ethanolic,
aqueous extracts and the essential oil of O. majorana could protect
against liver and kidney damage and genotoxicity induced by lead acetate
[100-102]. O. majorana has also been found to inhibit platelet adhesion
aggregation and secretion [103]. Furthermore, this plant exerts a low
cytotoxicity on several hepatoma cell lines [104]. It has been shown by Al
Harbi that an extract of O. majorana reduced the side effects induced by
cyclophosphamide, an established anticancer drug, without altering its
cytotoxicity [96].

In the present study, we investigated the effect of Origanum
majorana ethanolic extract (OME) on breast cancer cells. We examined
the effects of OME on cell viability, cell cycle, apoptosis and tumor
invasion and metastasis in the highly proliferative and invasive Estrogen
Receptor (ER)-negative mutant p53 breast cancer cell line MDA-MB-231.
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1.9.2. Microorganisms as Source of Anti-Cancer Agents
Many anti-cancer agents have been discovered by screening
natural products from a wide range of microorganisms. Toxins that
originally evolved to kill competing microorganisms can have a variety of
physiological effects in animals. In many cases, the targets of these
compounds are components of signal transduction cascades that are
conserved in many species, and that have been considered novel targets
for anticancer drug discovery [105].
Anti-tumor antibiotics are among the most important cancer
chemotherapeutic agents, and include members of the anthracycline,
bleomycin (isolated from Streptomyces verticillus and used in treatment of
germ-cell, cervix and head and neck cancers), actinomycin (isolated from
Streptomyces spp. and used to treat sarcoma and germ-cell tumors)
[106]. Clinically useful agents from these above families are the
daunomycin (isolated from Streptomyces coeruleorubidus and used to
treat leukemia) and related agents like doxorubicin, idarubicin, and
epirubicin (isolated from Streptomyces Pneuceticus and used in
lymphoma, sarcomas, breast, ovary, lung cancers).
Rapamycin and its analogs are products of Streptomyces
hygroscopicus that have potent immunosuppressive activity. They inhibit
the signaling pathways required for T-cell activation and proliferation.
Rapamycin blocks progression of the cell cycle at the middle-to-late G1
phase in T cells and B cells, and osteosarcoma and rhabdomyosarcoma
cell lines, among others [107]. Geldanamycin is a benzoquinone
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ansamycin natural fermentation product and inhibits the heat-shock
protein HSP 90 [108].
Wortmannin is a product of the fungus Talaromyces wortmanni and
inhibits signal transduction pathways by forming a covalent complex with
an active-site residue of phosphoinositide 3 kinase (PI3K), inhibiting PI3K
activity [109]. Others include also the peptolides (i.e. dactinomycin), the
mitosanes (such as mitomycin C) and the glycosylated anthracenone
mithramycin. The anthracyclines are among the most used anti-tumor
antibiotics in the clinic and exert anti-tumor activity mainly by inhibiting
topoisomerase II [110].
Anti-cancer agents from natural sources exert their toxicity through
modulation of several pathways and induction of different mechanisms of
cell death and growth inhibition. Such anti-cancer agents from natural
sources induce apoptosis, necrosis, growth arrest, senescence, and
autophagocytosis in several types of cancer. Growth inhibition and
induction of cell death are among the major objectives of anti-cancer
therapies.
1.9.2.1. Salinomycin
Salinomycin is a monocarboxylic polyether antibiotic, isolated from
Streptomyces

albus,

widely

used

as

an

antibiotic

to

prevent

anticoccidiosis in poultry and as growth promoter for ruminants and swine.
Screening for compounds that specifically target cancer stem cells has led
to the identification of Salinomycin as potential anticancer agent.
Salinomycin was shown to (i) selectively induce cell death in breast
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cancer stem cells in cell culture assay and (ii) inhibit breast tumor growth
in mice [111]. More recent investigations have reported that Salinomycin
possesses a potent anticancer activity against other cancer stem cells
such as the ALDH positive A549 lung cancer cells [112], ALDH gastric
cancer cells [113], and CD133+ subpopulations in human CRC HT29 and
SW480 colorectal cancer cells [114]. However, the mechanism of
Salinomycin's activity on cancer stem cells is yet to be elucidated.
More recent studies reported that Salinomycin shows efficacy
against other human cancer cells including those displaying drug
resistance [115]. Salinomycin was shown to act as a p-glycoprotein
inhibitor to overcome apoptosis resistance in cancer cells [116]. Lu, et al.,
2010, have shown that Salinomycin inhibits Wnt signaling and selectively
induces

apoptosis

in

chronic

lymphocytic

leukemia

cells

[117].

Salinomycin was also shown to induce apoptosis in human prostate
cancer cells by inducing an elevation in the intracellular reactive oxygen
species (ROS) levels and mitochondrial membrane depolarization [118].
Very recent studies have also shown that Salinomycin inhibits prostate
cancer growth and migration through the induction of oxidative stress
[119].
A combination treatment using Salinomycin with gemcitabine has
proven to be more effective than individual drugs against pancreatic
cancer cells [120]. It appears that Salinomycin sensitizes cancer cells to
the effects of etoposide and doxorubicin treatments by enhancing
apoptosis, increasing DNA damage and reducing the level of p21 protein
[121]. Indeed, Salinomycin sensitizes radiation-treated cells by inducing
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G2 arrest and causing DNA damage [122]. More recently, Salinomycin
was reported to sensitize cancer cells to antimitotic drugs (paclitaxel,
docetaxel, vinblastin and colchicine) by enhancing apoptosis as well as
preventing G2 arrest [123].
Despite the recent findings, the mechanisms underlying the
anticancer activity of Salinomycin are still poorly understood. In the
present study, we have investigated the effect of Salinomycin on MCF-7,
T47D and the triple negative MDA-MB-231 human breast cancer cell
lines.
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SPECEIFIC AIMS OF THE STUDY (OBJECTIVES)
1. Testing the efficacy of Origanum majorana plant extract and
Salinomycin against different types of human breast cancer in vitro
(cancer cell lines) and in vivo (chick embryo tumor growth and
metastasis assay).
In this study, the effects of this plant extract and this compounds on cell
viability, apoptosis, migration and invasion in vitro and the progression
and metastasis of human solid breast tumors in vivo were evaluated.
2. Identification of downstream biomarkers associated with response
to the treatment with selected active plant extracts.
Because most anticancer drugs are known to alter gene expression, we
examined the effects of the O. majorana extract and Salinomycin on the
expression of pathways (apoptosis, cell cycle…)- specific genes in several
breast cancer cell lines using western blot, immunofluorescence and RTPCR analysis.
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CHPATER 2: MATERIALS AND METHODS
2.1. Preparation of the Origanum majorana Ethanolic Extract
Origanum majorana commonly known as “marjoram” and used as a
culinary herb was obtained from a private commercial farm located in the
Tyre region of Lebanon. All necessary permits were obtained for the
harvesting of the leaves. 5.0 g of the dried leaves were ground to a fine
powder using a porcelain mortar and pestle. The powder was suspended
in 100 mL of 70% absolute ethanol and the mixture was kept in the dark
for 72 hours at 4°C in a refrigerator without stirring. The mixture was then
filtered through a glass sintered funnel and the filtrate was evaporated
using a rota-vapor at room temperature. The green residue was kept
under vacuum conditions for 2–3 hours and its mass was recorded.
2.2. Cell Culture and Reagents
Human breast cancer cells MDA-MB-231 and MCF-7 were
maintained in DMEM (Hyclone, Cramlington, UK) and the MDA-MB-23GFP used in this study was maintained as previously described [124]. The
T47-D breast cancer cells were maintained in RPMI 1640 (Hyclone). All
media were supplemented with 10% fetal bovine serum and 100U/ml
penicillin/streptomycin (invitrogen). HUVECs (Invitrogen, Carlsbad, CA,
USA) were maintained in MEM 199 supplemented with 20% FBS,
penicillin/streptomycin, 2 mM L-glutamine, 5U/ml heparin and 50 μg/ml
endothelial cell growth supplements (BD Biosciences, Bedfrord, MA,
USA). Salinomycin and 4-Hydroxy-Tamoxifen were purchased from
Sigma-Aldrich (Saint-Quentin Fallavier; France).
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Antibodies for p21

(556431), PARP (556494) were obtained from BD Pharmingen.
Antibodies for phosphor-H2A.X (ser139) (07-164), acetyl-Histone H3 (06599), acetyl-Histone H4 (06-866), phosphor-Histone H3 (ser10) (05-1336),
P53 (E26, 04-241), Cyclin B1 (05-373) and cyclin D1 (04-1151) were
obtained from Millipore. Antibodies for survivn (sc-1779), ICAM-1 (sc-107),
β-actin (C4, sc-47778), goat anti-mouse IgG-HRP (sc-2005) and goat antirabbit IgG-HRP (sc-2004) were obtained from Santa Cruz Biotechnology,
Inc. Antibodies to E-cadherin (ab15148), TNF- (ab9739) and uPAR (ab
103791) from Abcam. Antibodies to p27 (3686), NF-kB p65 (3034), pIB-α
(ser32) (2859) from Cell Signaling (Cell Signaling Technology, Inc.,
Danvers, MA, USA). AlexaFluor 488 goat anti-rabbit IgG (H+L) (A11008)
and AlexaFluor 594 goat anti-mouse IgG (H+L) (A11005) were obtained
from Invitrogen.
2.3. Cellular Viability
Cells were seeded in triplicate in 96-well plates at a density of
5,000 cells/well. After 24 hours of culture, cells were treated with
increasing concentrations of Salinomycin or OME and incubated for the
indicated time periods. Control cells were exposed to DMSO cells (in case
of Salinomycin) at a concentration equivalent to that of the Salinomycintreated or equal volume of 70% ethanol (in case of OME). In combination
experiments,

MCF-7

and

MDA-MB-231

cells

were

subjected

to

simultaneous treatment with 20 µM 4-hydroxy-tamoxifen A and 1µM
frondoside A, respectively, plus DMSO or increasing concentrations of
Salinomycin for 48 hours. The effects of Salinomycin, alone or in
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combination, on cell viability was determined using a CellTiter-Glo
Luminescent Cell Viability Assay (Promega Corporation, Madison, USA),
based on quantification of ATP, which signals the presence of
metabolically active cells. Luminescent signals were measured using a
Berthold FB12 Luminometer. The Data were presented as proportional
viability (%) by comparing the treatment group with the untreated cells, the
viability of which is assumed to be 100%.
Cell viability was also assessed using Trypan Blue Exclusion
Assay. Cells were plated onto 24-well plates (20 x 104 cells/well). The day
of the treatment the cells were counted to estimate the approximate
number of cells per well. Following Salinomycin treatment at indicated
times, cells were trypsinized, pelleted by centrifugation and resuspended
in serum free DMEM and stained with trypan blue. Dead (stained blue)
and live (unstained) cells were counted on a Neubauer Hemacytometer.
Three independent assays were performed in triplicate, and results were
reported as the means ± SEM.
2.4. Caspase 3/7, 8 and 9 activities
MDA-MB-231, MCF-7 cells were seeded at a density of 5,000 cells
/ well into a 96-well plate in triplicate and treated with the drugs for 24
hours and 48 hours. Caspase-3/7, 8 and 9 activities were measured using
a luminescent Caspase-Glo 3/7, Caspase8 and Caspase 9 assay kits
(Promega Corporation, Madison, USA) following the manufacturer’s
instructions. Caspase reagents were added to triplicate in the 96 wells.
The plate was mixed on an orbital shaker and incubated for 2.5 hours at
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room temperature in the dark. A luminescent signal was measured as
described above.
2.5. Senescence Associated-β-Galactosidase (SA-β-gal) Staining
2.5 x105 MDA-MB-231 cells were cultured in 60mm culture dishes
for 24 hours and then exposed to Salinomycin 10µM or DMSO for 96
hours. Treatment and control cells were then washed in PBS, and fixed
with 2% formaldehyde/ 0.2% glutaraldehyde for 5 minutes at room
temperature. The SA-β-gal staining was conducted as previously
described [125]
2.6. Flow Cytometric Analysis of Cell Cycle
MDA-MB-231 cells (1.8 x106) were seeded in 100mm culture
dishes and cultured for 24 hours before the addition of either OME extract
or Salinomycin at the concentrations indicated in the results part. After
incubation, cells were harvested, washed twice with ice-cold PBS,
resuspended in 500µl PBS, fixed with an equal volume of 100% ethanol
and incubated for at least 12 hours at -20ºC. Cells were then pelleted,
washed twice with PBS, permeabilized in 0.1% Triton X-100/PBS for 15
minutes on ice, pelleted and then resuspended in PBS containing 40µg/ml
propidium iodide and 25µg/ml RNase A, at 37ºC for 30 minutes. Cells
were analyzed using BD FACSCanto II (Becton Dickinson). Data
acquisition was conducted using FACSDiva 6.1 software. The percentage
of cells in the G1, S and G2/M phases were determined using the FlowJo
software.
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2.7. Quantification of Apoptosis by Annexin V /Propidium iodide (PI)
Staining
DMSO and Salinomycin-treated MDA-MB231 (1.8 x 106) cells
grown in 100mm culture dishes were harvested by trypsin release and
washed twice with ice-cold PBS. Apoptotic cell death was determined
using the BD FITC Annexin V Apoptosis Detection Kit II (BD Biosciences)
according to the manufacturer’s instructions. Cell samples were analyzed
using the BD FACSCanto II (Becton Dickinson).
2.8. Immunofluorescence Staining
MDA-MB 231 cells (4 x104) were grown on 4 well labtek chamber
slide (Becton Dickinson) for 24 hours, and then treated with vehicle as
control or either OME extract or Salinomycin for 24 hours at the
concentrations indicated in the results come later. Cells were then fixed in
10% formalin solution (4% paraformaldehyde) (Sigma-Aldrich; SaintQuentin Fallavier, France) for 5 minutes at room temperature followed by
permeabilization in PBS containing 0.1% Triton X-100 for 5 minutes at
room temperature. Cells were then washed three times with PBS, blocked
with 5% non-fat dry milk in PBS for 30 minutes at room temperature and
then incubated with the primary antibody diluted in 1% non-fat dry
milk/PBS overnight at 4ºC. Following incubation, cells were washed three
times with PBS and incubated for 1 hour at room temperature in the
presence of rhodamine-conjugated or fluorescein-conjugated secondary
antibody diluted at 1:200 in 1% non-fat dry milk/PBS. After washing with
PBS, cells were mounted in Fluoroschield with DAPI (Sigma-Aldrich) and
examined under Nikon Ti U fluorescence microscope.
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2.9. Colony Formation Assay in Soft Agar
Assays were performed in six-well plates. The lower (base) layer
consisted of 1 ml 2.4% Noble Agar. The base layer was overlaid with a
second layer consisting of 2.9 ml growth medium, 0.3% Noble Agar, and 3
× 104 MDA-MB-231 cells. Agar at 50°C was mixed with the medium at
37°C, plated, and left to set for 10 minutes. Growth medium was then
added and plates incubated at 37oC. Cells were allowed to grow to form
colonies for 14 days before treatment with either Salinomycin or OME
extract. Colonies were allowed to grow for one more week. Following
treatment, plates were washed twice with PBS and then colonies were
fixed with 10% ice-cold methanol for 10 min and washed once with PBS.
Colonies were allowed to stain for 1 hour in a solution containing 2%
Giemsa. The size of the colonies was measured, using a microscope
(10X) and the colony size was categorized as Large (>400 µm), medium
(200-400 µm), or small (50-200 µm). Colony sizes were expressed as a
percentage of total counted colonies and then compared to the vehicle
treated controls (DMSO). The experiment was repeated three times.
2.10. Nuclear and whole Cell Extract and Western Blot Analysis
Cells (1.8 x 106) were seeded in 100mm culture dishes and
cultured for 24 hours before the addition of various concentrations of
either Salinomycin or OME extract. For whole cell lysates, following
incubation, cells were washed twice with ice-cold PBS, scraped, pelleted
and lysed in RIPA buffer (89900, Pierce) supplemented with a
protease/phosphatase

inhibitor

cocktail

(1861281,

Pierce).

After

incubation for 30 minutes on ice, cell lysates were centrifuged at 14,000
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rpm for 20 minutes at 4ºC. Nuclear extract were prepared from vehicle-or
OME-treated MDA-MB-231 cells using the NE-PER extraction reagents
(Thermo Scientific, Rockford, IL, USA). The protein concentration of the
lysates was determined using BCA Protein Assay Kit (23225, Thermo
Scientific) and the lysates were adjusted with lysis buffer. Aliquots of 25
µg of total cell lysate were resolved onto 10-12% SDS-PAGE. Proteins
were transferred to nitrocellulose membranes (88018, Thermo Scientific)
and blocked for 1 hour at room temperature with 5% non-fat dry milk in
TBST (TBS and 0.05% Tween 20). Incubation with specific primary
antibodies was conducted in a blocking buffer overnight at 4ºC.
Horseradish peroxidase-conjugated anti-IgG was used as secondary
antibody. Immunoreactive bands were detected by ECL chemiluminescent
substrate (32209, Thermo Scientific). Also when needed, membranes
were stripped in a Restore Western Blot Stripping Buffer (21059, Thermo
Scientific) according to the manufacturer’s instructions.
2.11. Wound Healing Migration Assay
MDA-MB-231 cells were grown in six-well tissue culture dishes until
confluence. A scrape was made through the confluent monolayer with a
sterile plastic pipette tip of 1mm diameter. Afterwards, the dishes were
washed twice with PBS and incubated at 37°C in fresh DMEM
complemented with 10% fetal bovine serum in the presence or absence of
the indicated concentrations of OME. At the bottom side of each dish,
three arbitrary places were marked where the width of the wound was
measured with an inverted microscope (objective x 10). Wound closure
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was expressed as the average ± SEM of the difference between the
measurements at time zero and a 10 hours' time period.
2.12. Migration Chamber Assay
5 x 104 cells were seeded in the upper chamber, HTS Multiwell
Insert System (BD Biosciences, Franklin Lakes, NJ, USA), in serum-free
medium, with or without OME and migration assay, A serum-containing
medium was added to the lower chamber to act as a chemotactic
attractant. After 6 hours of incubation, cells were washed with PBS, and
fixed with formaldehyde. Cells were then stained with 1% crystal violet for
10 minutes. After washing with PBS, cells from at least 5 different random
fields were counted under a microscope.
2.13. Aggregation Assay
Growing cells were detached using a 2mM EDTA in calcium
magnesium-free PBS (CMF-PBS). A cell suspension of 1 x 106 cells/ml
was aliquoted into microcentrifuge tubes, washed with PBS, resuspended
in a 1ml culture media and incubated with or without OME on a rocker for
1 hour at 37°C. Cells were then fixed with 1% formaldehyde and pictures
taken under an inverted microscope (Olympus IX71). Aggregation was
calculated as previously reported [126] using the following equation: %
aggregation= (1-Nt/Nc) x 100, where Nt and Nc represent the number of
single cells in treatment and untreated groups, respectively.
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2.14. Adhesion Assay
Adhesion of MDA-MB-231 to HUVECs was performed as
previously described [127] with minor modifications. Cell culture plates
were coated with collagen and HUVECs grown to confluent monolayers.
TNF-α (25ng/ml) was added for 6 hours to stimulate HUVECs prior to the
addition of MDA-MB-231 cells. MDA-MB-231 transfected with Renilla
Luciferase were resuspended in HBSS containing a 1% BSA at a
concentration of 2x105 cells/ml. 150 µl of this cell suspension was added
to the upper chamber containing confluent HUVECs in the absence or
presence of OME. After 1 hour, unattached cells were removed by gently
washing the plates three times with PBS. Adherent cells were lysed using
a luciferase lysis buffer (Promega, Madison, WI, USA) and light units were
measured.
2.15. Matrigel Invasion Assays
The invasiveness of the MDA-MB-231 cell was treated with the
indicated concentrations of OME and tested using a BD Matrigel Invasion
Chamber (8-µm pore size: BD Biosciences, Bedfrord, MA, USA). MDAMB-231 (1 x 105) cells were placed in 0.5 mL of media containing vehicle
or the indicated concentrations of OME were seeded into the upper
chambers of the system. The bottom wells in the system were filled with
DMEM complemented with 10% fetal bovine serum as a chemo-attractant
and then incubated at 37°C for 24 hours. Non-penetrating cells were
removed from the upper surface of the filter with a cotton swab. Cells that
have migrated through the matrigel were fixed with 4% formaldehyde,
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stained with DAPI and counted in 6 random fields under a microscope.
For quantification, the assay was done in duplicate then and repeated
three times.
2.16. Measurement of Matrix Metalloproteinases by ELISA
Cells were seeded in 6-well plates in the absence of vehicle or
OME for 24 hours. The conditioned medium was collected and the levels
of MMP-2 and MMP-9 secreted were determined using immunoassay kits
(Invitrogen, Camarillo, CA, USA). The experiments were repeated three
times and the average of the three means was represented as ± SEM.
2.17. Gelatin Zymography
Gelatin zymography was conducted as previously described [128].
MDA-MB-231 (2.5 x 106) cells were incubated in serum-free DMEM for 24
hours in the presence of vehicle or OME (150 and 300 µg/mL). The
conditioned medium was collected, concentrated and 30 μg of total
protein was resolved in 10% polyacrylamide gel containing 0.1% gelatin.
After electrophoresis, the gel was washed for 1 hour in 2.5% (v/v) Triton
X-100 to remove SDS and then incubated overnight at 37°C in 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 0.5 mM ZnCl2 and 10 mM CaCl2 to allow
proteolysis of the gelatin substrate. Bands corresponding to activity were
visualized by negative staining using 0.5% Coomassie brilliant blue R-250
(Bio-Rad, Hercules, CA, USA). Representative results from two
independent experiments are shown. Densitometry was conducted using
ImageJ software and the band density was normalized to the non-specific
band staining on the gel.
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2.18. Quantitative Immunoassay for Human Vascular Endothelial
Growth Factor (VEGF)
MDA-MB-231 cells (1.5 x 105) were seeded in 24-well plates. The
conditioned medium was collected and the level of VEGF measured using
a VEGF Enzyme-Linked Immunosorbent Assay Kit (R&D Systems,
Minneapolis, MN, USA. Assays were performed in triplicate and three
independent experiments were conducted. The data is presented as mean
values ± SEM.
2.19. Quantification of Nitrate/Nitrite Production
The amount of nitrate/nitrite production was determined with a
colorimetric ELISA Kit (Cayman Chemical, Ann Arbor, Michigan, USA),
which is based on the Griess reaction. The value of nitrate/nitrite
presented is the total value measured in the presence of cells minus the
value determined from the media alone in the absence of any growing
cells.
2.20. Luciferase Activity
MDA-MB-231 cells were seeded in 12-well plates the day before
transfection. Cells were then transfected with the E-cadherin Luciferase
Reporter Expression Plasmid [129] using Lipofectamine 2000 (Life
Technologies, Inc. Grand Island, NY, USA). Cells were allowed to recover
for 4 hours after transfection in OPTI-MEM (Life Technologies, Inc., Grand
Island, NY, USA) which was then replaced with a complete medium.
Luciferase activity was measured using Dual Luciferase Reporter Assay
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System (Promega, Madison, WI, USA). Renilla Luciferase reporter was
used as an internal control, to which firefly luciferase values were
normalized. Experiments were repeated three times and the average of
the three means was represented ± SEM.
2.21. Transendothelial Migration Assay
Transendothelial migration of MDA-MB-231 through HUVEC was
conducted as previously described [130]. Transwell filters were coated
with collagen and allowed to dry overnight. HUVECs (2 X 10 5/well) were
then seeded onto the rehydrated membrane and allowed to grow until a
confluent monolayer was formed. TNF-α (25ng/ml) was added for 6 hours
to stimulate HUVECs. Then, MDA-MB -231 cells (1 x 106) were loaded on
top and incubated overnight in the absence, or presence, of OME. Cells
on the upper chamber were removed with a cotton swab, whereas MDAMB-231 on the bottom were stained and quantified as previously reported
[130].
2.22. RNA Extraction and RT-PCR
Total RNA from vehicle- or OME-treated MDA-MB-231 cells were
prepared using Trizol reagent (Life Technologies, Inc. Grand Island, NY,
USA). The RNA expression of MMP-2 and MMP-9 was determined by RTPCR. RT-PCR was performed using the Qiagen OneStep RT-PCR Kit
(Qiagen, Hilden, Germany). Equal amounts of RNA (500 ng) were used as
templates in each reaction. The sequences of specific primers were as
follows: MMP-2 sense, 5′-TCTCCTGACATTGACCTTGGC-3′, and
antisense: 5′-CAAGGTGCTGGCTGAGTAGATC-3′; MMP9 sense, 5′35

TTGACAGCGACAAGAAGTGG-3′, and antisense, 5′CCCTCAGTGAAGCGGTACAT-3′; GAPDH sense, 5′GGCCTCCAAGGAGTAAGACC-3′, and antisense: 5′AGGGGTCTACATGGCAACTG-3′. The PCR products were separated by
1.5% agarose gel and visualized by ethidium bromide staining.
Representative results from two independent experiments are shown.
2.23. Chick Embryo Tumor Growth and Metastasis Assay
The chick embryo tumor growth assay was performed as previously
described [131] with slight modifications. According to French legislation,
no ethical approval is needed for scientific experimentation using
oviparous embryos (decree n°2013-118, February 1, 2013; art. R-214-88).
This work was done under animal experimentation permit N°381029
issued

to

Jean

Viallet

and

animal

experimentation

permit

N°

B3851610001 issued to Institute Albert Bonniot. Fertilized White Leghorn
eggs (Société Française de Production Agricole, St. Brieuc, France), were
incubated at 38°C with 60% relative humidity for 10 days. At stage E10,
the chorioallantoic membrane (CAM) was dropped by drilling a small hole
through the eggshell into the air sac and a 1 cm2 window was cut in the
eggshell above the CAM. Cultured MDA-MB-231-GFP were detached by
trypsinization, washed with complete medium and suspended in serum
free DMEM. A 50 µl inoculum of 1 X 10 6 MDA-MB-231-GFP cells was
added onto the CAM of each egg (eggs were randomized in 4 groups of
15). One day later, tumors that began to be detectable were treated every
second day at E11, E13, E15 and E17 by dropping 100 µl of either OME
(300 µg/mL or 450 µg/mL), colchicine (2µM) or 0.02 % ethanol (vehicle) in
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PBS onto the tumor. At E19 the upper portion of the CAM was removed,
transferred in PBS and the tumors were then carefully cut away from
normal CAM tissue and weighted. In parallel, a 1 cm 2 portion of the lower
CAM was collected to evaluate the number of nodules, containing GFPexpressing cells. The fluorescent nodule were visualized in situ using
whole mounts of tissue fixed in 4% formaldehyde in PBS and flattened
between a hollow glass slide and a thick coverslip. In order to number the
nodules, a thorough and complete visual scan of the piece of the lower
CAM was done using a fluorescent microscope. Chick embryos were
sacrificed by decapitation.
2.24. Statistical Analysis
Results were expressed as means ± SEM of the number of
experiments. A p value of < 0.05 was considered statistically significant.
Student’s t-test was used to detect the difference between the two values.
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CHAPTER 3: RESULTS AND DISCUSSION
Part I. Anti-breast cancer activity of Salinomycin
3.1 Growth Inhibitory Effect of Salinomycin on MDA-MB-231, MCF-7
and T47D Breast Cancer Cell Lines
To examine the anticancer activity of Salinomycin on breast cancer
cells, we first measured the effect of various concentrations of
Salinomycin (1, 2.5, 5, 10, 25 and 50 µM) on the proliferation of three
different breast cancer cell lines (MDA-MB-231, MCF-7 and T47D). The
data obtained is summarized in figure 1. Our results show that exposure
of the three cell lines to Salinomycin decreased cellular viability in
concentration and in a time-dependent manner. However, the growth
inhibitory effect of Salinomycin appears to be more pronounced in MCF-7
and T47D than in MDA-MB-231. The IC50 (producing half-maximal
inhibition) at 24 hours was approximately 40 µM for the MCF-7 and T47D
(fig. 2 and 3) while the same concentration gave only about 35% inhibition
of proliferation in the MDA-MB-231 cells (fig. 1). Following 48 hours of
treatment, IC50 was 15 µM for the MCF-7 and T47D (fig. 2 and 3) and
approximately 35 µM for the MDA-MB-231 cells. Maximal inhibition (90%,
P<0.05) of cell growth was observed with 50µM for the MCF-7 and T47D
cell lines. The same concentration gave approximately 70% inhibition of
proliferation of the MDA-MB-231cell lines (fig.1). Taken together, our data
show that Salinomycin inhibits cell growth of breast cancer cell lines in a
concentration and time-dependent manner and that MCF-7 and T47D
exhibit a greater sensitivity to Salinomycin compared to the MDA-MB-231
cells.
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Figure 1. Inhibition of Cellular Viability of MDA-M-231 Cells by
Salinomycin.

Figure 2. Inhibition of Cellular Viability of MCF-7 Cells by Salinomycin.
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Figure 3. Inhibition of Cellular Viability of T47-D Cells by Salinomycin.

Figure 4. Cell Viability of MDA-MB-231 Cells in Response to Various
Concentrations of Salinomycin Using Trypan Blue Exclusion Dye Assay.
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We next focused only on the highly proliferative and invasive
Estrogen Receptor (ER)-negative, mutant p53 breast cancer cell line
MDA-MB-231 to investigate the mechanism by which Salinomycin
decreased cell viability.
In order to distinguish between cell death and the possible growth
arrest effects of Salinomycin, cell viability of the MDA-MB-231 cells was
monitored by using the trypan blue exclusion dye assay at 24 and 48
hours after the Salinomycin treatment. As it is shown in Figure 4, Trypan
Blue Assay also showed a dose- and time-dependent decrease in viability
in Salinomycin-treated cells when compared to the control cells.
However, a closer look to the number of viable (Trypan Blue Negative)
cells counted in each treatment, revealed that the number of cells after
treatment with 2.5, 5 and 10 µM did not significantly change at 24 and 48
hours and moreover, was comparable to the number of cells counted at
the day of treatment (Table 1) with a very low percentage of cell death
(Trypan Blue Positive) suggesting that proliferation of the MDA-MB-231 at
these concentrations is inhibited and cell death is minimal (Table 1) .
Interestingly, at higher concentrations of Salinomycin (25 and 50 µM), the
number of viable MDA-MB-231 cells showed a steady decline after 24 and
48 hours indicative of cell death. The number of viable cells compared to
the day of treatment, dropped to 58% and 42% at 25 µM and to 48 and
28% at 50 µM.
Comparative analysis of cell viability between CellTiter-Glo and
Trypan Blue Exclusion assay shows that cell viability data obtained by
CellTiter-Glo and trypan blue exclusion assays are not perfectly super24

imposable (fig. 5 and 6). As a matter of fact, the same concentration of
Salinomycin gave slightly different IC50 between Trypan Blue Exclusion
and CellTiter-Glo assay.

Salinomycin
(µM)

Dead cells (number and %)
24 hours

Viable cells (number and
%)

48 hours

24 hours

48 hours

2311 (2%)

64122
(100%)

143055
(100%)

Control

589 (1.0%)

2.5

1078 (2.0%)

1444 (2.0%) 48822 (76%) 63688 (45%)

5

1844 (4.0%)

2700 (4.0%) 46877 (73%) 55400 (39%)

10

2244 (6%)

3244 (7%) 39322 (61%) 43844 (31%)

25

4478 (17%)

6978 (27%) 23288 (36%) 19377 (41%)

50

2156 (12%)

12089 (50%) 16244 (25%) 11333 (8%)

* Number of cells counted at the day of treatment (0h) approximately
39000

Table 1. Viability of MDA-MB-231 Cells in Response to Salinomycin
Determined by Trypan Blue Exclusion Assay.
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Cell Viability (% of control)
CellTiter Glo vs Trypan Blue
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Figure 5. Cell Viability of the MDA-MB-231 Cells in Response to
Salinomycin After 24 Hours Determined by Trypan Blue Exclusion Dye
and CellTiter-Glo Assays.
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Figure 6. Cell Viability of MDA-MB-231 Cells in Response to Salinomycin
After 48 Hours Determined by Trypan Blue Exclusion Dye and CellTiterGlo Assays.
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3.2 Salinomycin Induces Morphological Changes in MDA-MB-231
Cells
Light microscopy observation of Salinomycin-treated MDA-MB-231
cells revealed morphological changes induced by this compound. As
shown in figure 7, MDA-MB-231 cells treated with concentrations of
Salinomycin 5, 10 and 25 µM, underwent morphological changes
characterized by a loss of their epithelial morphology visible after 24 hours
of treatment. These cells appeared dispersed and exhibited fibroblast-like
morphology with filopodia-like extensions and central nuclei. However, the
fibroblast-like morphology observed in

these cells is not due to

an

epithelial-mesenchymal transition, since no changes in levels of vimentin
and E.cadherin proteins was detected by a western blot analysis (fig. 8)
and immunofluorescence (fig. 9). Interestingly, a subpopulation of MDAMB-231 cells treated with low concentration of Salinomycin exhibited a
senescence-like phenotype characterized by cell size increase and
flattening shape compared to the control cells (fig. 7 arrows). At higher
concentrations of Salinomycin (25 and 50µM), cells appeared smaller and
rounded, characteristic of cells undergoing apoptosis. Strikingly, lower
concentrations of Salinomycin up to 10 µM did not lead to further change
in cell morphology nor to cell density after 72 hours exposure to
Salinomycin (fig 10). In contrast higher concentrations (25 and 50) led to
fewer cells on the plate and further rounded cells. These morphological
changes seem to be specific to MDA-MB-231 cells, since no obvious
changes were observed in the MCF-7 and T47D cell lines.
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Figure 7. Morphological Changes Observed in the MDA-MB 231 Cells
After 24 Hours of Treatment with Various Concentration of Salinomycin.

Figure 8. Western Blot Analysis of Vimentin and E-cadherin Expression in
Salinomycin Treated MDA-MB-231 Cells.
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Figure 9. Immunofluorescence Staining for Vimentin in Salinomycin
Treated MDA-MB-231 Cells.

24
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10 µM
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50 µM

Figure 10. Morphological Changes Observed in the MDA-MB 231 Cells
After 72 Hours of Treatment with Various Concentrations of Salinomycin.
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3.3 Salinomycin Induces Apoptosis in MDA-MB-231 Cells
Salinomycin was reported to mediate apoptosis in many human
cancer cells [115]. Therefore, we investigated whether the observed
inhibition of cell viability upon Salinomycin treatment in the MDA-MB-231
cells was associated with the induction of apoptosis. Flow cytometry
analysis of Annexin V and Propidium Iodide (PI) stain was used to
determine the percentage of apoptotic cells induced by Salinomycin after
24 hours of treatment. Treatment with 5 and 10 µM Salinomycin did not
lead to a change in the early stage (Annexin V +/PI-) nor in the late stage
apoptotic cells (Annexin V+/PI+)/necrotic cells suggesting the absence or
minimal cell death in these populations (fig. 11). However, higher
concentrations (25 µM) led to an increase in both early and late
apoptotic/necrotic cell population.
Immunofluorescence microscopy was also used to confirm
apoptosis in the Salinomycin-treated cells. Fluorescence staining of
Annexin V was detected only in cells treated with 25 µM of Salinomycin
(fig. 3B, lower panel), while no Annexin V staining was detected at a
concentration of 10 µM (fig. 12, middle panel) or lower concentrations,
further confirming the absence of apoptosis in these cells. Interestingly,
the proportion of dead cells detected by Trypan Blue Exclusion Assay at
25 µM was higher than the proportion of apoptotic cells detected by flow
cytometry suggesting that apoptosis might account only partly for the cell
death induced by high concentrations of Salinomycin.
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Figure 11. Salinomycin induced apoptosis in the MDA-MB-231 cells.
Annexin V binding was carried out using Annexin V-FITC Detection Kit.

Figure 12. Immunofluorescence Staining for Annexin V-FITC in
Salinomycin Treated MDA-MB-231 Cells.
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Apoptosis was further examined by measuring Caspase 3/7
activation in MDA-MB-231 cells treated with low (10µM) or high
concentrations (50µM) of Salinomycin after 24 and 48 hours of treatment.
Consistent with Annexin V staining, Caspase 3/7 activation was detected
in cells treated with 50µM but not in cells treated with 10µM (fig. 13).
Furthermore, as figure 14 shows, PARP cleavage occurred only in cells
treated with higher concentrations of Salinomycin (25 and 50µM), while no
cleaved PARP is detectable at lower concentration of Salinomycin (5 and
10µM). The lack of Caspase 3/7 activation and cleavage of PARP in MDAMB-231 suggest that the reduced cell viability observed in MDA-MB-231
cells treated with low concentrations of Salinomycin (≤10µM) resulted from
an inhibition of cell proliferation and was not caused by cell death.

Figure 13. Stimulation of Caspase 3/7 Activity in MDA-MB-231 Cells After
Exposure to Salinomycin (10 and 25 µM) for 24 and 48 Hours.
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Figure 14. Western Blot Analysis Showing Dose-and Time-Dependent
Induction of PARP Cleavage in Salinomycin Treated MDA-MB-231 Cells.
* represents non-specific band

3.4 Salinomycin Induces Growth Arrest in MDA-MB-231 Cells and
Inhibited Colony Growth
To confirm that low concentrations of Salinomycin induced growth
inhibition of MDA-MB-231, cells were treated with DMSO or Salinomycin
(2.5 and 5 µM) and kept in a culture for 6 days then cell viability was
measured after 1, 3 and 6 days by counting viable cells using Trypan Blue
Exclusion Assay. Figure 15 clearly shows that while DMSO treated MDAMB-231 cells continued to proliferate, Salinomycin-treated cells exhibited
a strong inhibition of proliferation. Moreover, the inhibition of cellular
proliferation induced by low concentrations of Salinomycin persisted even
upon removal of the drug further indicating that, a low concentration of
Salinomycin induces a permanent cell cycle arrest of the MDA-MB-231
cells. These results along with the cell viability data strongly suggest that
Salinomycin has a differential effect on the MDA-MB-231 cells depending
on the concentration used. At low concentrations, Salinomycin inhibits
24

cellular

proliferation

without

inducing

cell

death,

while

at

high

concentrations it exerts its effects by inducing apoptosis through activation
of caspase 3/7 and PARP cleavage.
To further confirm the growth arrest potential of Salinomycin on
MDA-MB-231 cells, we sought to determine if Salinomycin inhibits the
growth of formed colonies. Figure 16 shows that the size of a control
group of DMSO-treated colonies kept growing after three weeks
compared to the size of the control colonies at two week; more large and
medium size colonies are obtained in the three week plate, while fewer
small colonies were counted, indicating that medium colonies became
larger in size and smaller ones became medium sized colonies.
Interestingly, the colony sizes counted in the three week Salinomycintreated plates were indistinguishable from those in the two week control
DMSO-treated plates, indicating that Salinomycin was able to completely
block the growth of the MDA-MB-231 colonies. This data further confirms
the growth inhibitory effect of low concentrations of Salinomycin on the
proliferation of MDA-MB-231 cells.
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Figure 15. Inhibition of Proliferation by Salinomycin in MDA-MB-231
Cells.
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Figure 16. Induction of Growth Arrest by Salinomycin in MDA-MB-231
Cells.

3.5 Salinomycin Induced G2 Arrest and Senescence in MDA-MB-231
Cells
To examine the mechanism for Salinomycin-induced growth
inhibition, cell cycle distribution was analyzed by flow cytometry. MDAMB-231 cells were treated with the indicated concentrations of
Salinomycin (5, 10 and 25 µM) for 24 and 48 h.
As shown in figure 17, the concentration of Salinomycin at 10 and
25 µM caused an obvious G/2M arrest to the MDA-MB231 cells in a
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concentration and time-dependent manner. The population of G2/M
increased from 28% in DMSO-treated cells to 33 and 44% at 24 hours,
respectively (fig. 17, upper panel). Similarly, the G2/M population
increased from 22 to 43.6 and 49.67% at 48 hours, respectively (fig. 17,
lower panel). Surprisingly, at lower concentration (2.5 and 5 µM),
Salinomycin was found to induce a transient cell cycle arrest in G1 and
G2/M over time. In fact, Salinomycin induced an accumulation of cells in
G1 phase at 24 hours and successive accumulation in the G2 phase at 48
hours post-treatment.
To determine whether Salinomycin induced cell cycle arrest
specifically at mitosis or G2 phase, we examined the phosphorylation
status of Histone H3 (Ser 10). Histone H3 is phosphorylated at serine 10
during mitosis by aurora kinase and the phosphorylation status of H3 is
considered as a marker of mitosis [132]. We therefore, investigated the
expression of p(ser10)H3 and found a time and dose-dependent decrease
in the phosphorylation level of Histone H3 in response to the Salinomycin
treatment (fig. 18, upper panel) . This result indicated that Salinomycin
induced G2 arrest of MDA-MB231 cells. We also examined the expression
of cyclin B1 in Salinomycin treated cells. An accumulation of cyclin B1 is
well known to play an important role in G2/M transition. Knock-down of
cyclin B1 with siRNA produces cell cycle arrest predominantly in the G2
phase [133], while an upregulation of cyclin B1 invokes mitotic arrest
[134]. We found that Salinomycin also decreased cyclin B1 level in a timeand dose-dependent manner (fig. 18. middle panel), further confirming
that Salinomycin induced a cell cycle arrest in the G2 phase in MDA-MB-
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231 cells. However, a sensitive decrease of cyclin B1 began at higher
concentrations of Salinomycin.
G1 arrest observed at 24 hours with low concentrations of
Salinomycin prompted us to examine the expression levels of cyclin D1
protein involved in the control of the G1/S transition. It has been shown
that overexpression of cyclin D1 shortens the G1 phase and occurs in
many types of human cancers, whereas inhibition of cyclin D1 expression
blocks G1-S transition [135-137]. As shown in Figure. 18 (lower panel),
the level of cyclin D1 decreased upon treatment with Salinomycin in a
time- and dose-dependent manner. Remarkably, no cyclin D1 protein was
detected at 48 hours with a high concentration of Salinomycin.
MDA-MB-231 cells treated with low concentrations of Salinomycin
exhibited the behavior of senescent cells characterized by cell viability;
metabolically active and permanently growth arrested. Therefore, we next
determined whether the growth arrested MDA-MB-231 cells did indeed
undergo senescence. It is well known that senescent cells express a
senescence-associated β-galactosidase (SA-β-Gal), which is detected by
incubating cells with X-gal at a pH of 6.0. Our results show that 30% of
Salinomycin-treated

cells

expressed

SA-β-galactosidase

(fig.

19),

indicating that induction of senescence contributes to the inhibitory effect
of Salinomycin on the proliferation of MDA-MB-231 cells.
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Figure 17. Flow Cytometry Analysis of Salinomycin-induced G2 Cell-Cycle
Arrest in MDA-MB-231 Cells.

Figure 18. Western Blot Analysis of p(ser10) histone H3, cyclin B1 and
cyclinD1 Expression in Salinomycin Treated MDA-MB-231.
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Figure 19. Salinomycin Induced Senescence in MDA-MB-231 Cells After
Incubated with 5 µM Salinomycin for 96 Hours and Stained for SA-βGalactosidase Activity.

3.6 Salinomycin Induced activation of γH2AX, a Marker of Double
Strand Breaks, in MDA-MB 231 Cells
Several studies showed that cells can undergo premature
senescence in response to exposure to oxidative or genotoxic stresses
that cause DNA damage. Interestingly, Salinomycin was shown to induce
an elevation in the intracellular reactive oxygen species (ROS) levels and
mitochondrial membrane depolarization [118]. Moreover, Salinomycin was
also shown to induce DNA damage in MCF-7 and Hs578T human breast
cancer cells [121, 122]. Therefore, we sought to investigate whether
Salinomycin induced DNA damage in MDA-MB-231 cells as well. For this
purpose, MDA-MB-231 cells were cultured for 6, 24 and 48 hours in
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complete media containing either DMSO or an increasing concentration of
Salinomycin (5-50 µM). DNA damage was determined by measuring the
levels of phosphorylated H2AX (γH2AX) in non-treated and Salinomycintreated cells. Western blot analysis revealed a concentration- and timedependent increase in the levels of γH2AX (fig. 20) in the MDA-MB-231
cells in response to the Salinomycin treatment, indicating an accumulation
of double strand breaks in these cells. An increase in DNA damage was
also assessed by immunofluorescence staining of γH2AX in cells treated
with 10 and 50µM Salinomycin for 24 hours. Figure 21 clearly shows a
concentration-dependent increase of γH2AX foci in response to
Salinomycin. Since the activation of γH2AX occurs even at concentrations
of Salinomycin that do not lead to cell death (5 and 10µM), this rules out
the possibility that the resulting DNA damage is a consequence of DNA
fragmentation resulting from Caspase 3/7 activation and further confirming
the potential of this drug to induce double strand DNA breaks in a
concentration-dependent manner.

Figure 20. Western Blot Analysis of Phosphor-H2AX (Ser 139) in MDAMB-231 Cells Treated for 6, 24 and 48 Hours with DMSO or Indicated
Concentrations of Salinomycin.
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Figure 21. Immunofluorescence Staining for γH2AX in Salinomycin
Treated MDA-MB-231cells.

3.7 Salinomycin Induced p53-Independent Upregulation of p21waf/cip
in Growth Arrested MDA-MB-231 Cells
Because p21 protein has been reported to inhibit growth and
apoptosis and mediate senescence, we investigated whether the growth
inhibition and senescence mediated by Salinomycin was associated with
an induction of p21. MDA-MB-231 cells were cultured in the presence of
DMSO or an increasing concentration of Salinomycin for 6, 24 and 48
hours. Western blot analysis of p21 level in Salinomycin-treated cells with
concentrations causing growth arrest and senescence showed an
increase in the protein level detected starting from 6 hours of treatment
(fig. 22). At the concentrations of Salinomycin causing cell death, we
observed that while a concentration of 50 µM caused a quick decrease of
56

p21 level detected as early as 6 hours, a concentration of 25 µM,
however, led to a transient increase of p21 at 6 hours followed by a
decline in the protein level at 24 and 48 hours (fig. 22).

These

observations were further confirmed by immunofluorescence staining of
p21 in cells treated with 10 µM Salinomycin (fig. 23). As expected, no
induction of mutant p53 in the MDA-MB-231 cells was observed, thus
strongly suggesting that the induction of p21 by Salinomycin in MDA-MB231 cells occurred independently of p53 function.
The levels of another CDK inhibitor, p27 was also determined at 24
and 48 hours post-treatment. As it is shown in figure 24, the level of p27
showed a concentration and time-dependent decrease in MDA-MB-231
cells.

Figure 22. Western Blot Analysis of p21 Expression in Salinomycin
Treated MD-MB 231 Cells.
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Figure 23. Immunofluorescence Staining for p21 in Salinomycin Treated
MDA-MB-231Cells. DAPI is used as a nuclear stain.

Figure 24. Western Blotting Analysis of p27 Expression in MDA-MB-231
Cells upon Salinomycin Treatment.

3.8 Salinomycin Induced Downregulation of Survivin Expression in
MDA-MB-231 Cells
Survivin, a member of the inhibitor of apoptosis protein (IAP) family,
plays an important role in both the regulation of cell cycle and the
inhibition of apoptosis. However, a decrease in survivin levels has been
shown to sensitize cells to apoptosis. Therefore, we examined the
possible involvement of survivin in cell cycle arrest and apoptosis as
triggered by Salinomycin. Toward this end, we analyzed, by Western
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blotting, the expression of survivin in response to various concentrations
of Salinomycin after 24 and 48 hours of treatment. As shown in figure 25,
while low concentrations of Salinomycin led to no obvious change in
survivin expression, higher concentrations (25 and 50 µM), caused a
drastic decrease in survivin protein level at 24 and 48 hours, consequently
sensitizing MD-MB-231 to cell death. The persistence of survivin
expression at concentrations causing growth arrest and senescence could
also account for the resistance to cell death of Salinomycin-treated cells.

Figure 25. Western Blot Analysis of Survivin Expression in SalinomycinTreated MDA-MB 231 Cells.

3.9 Salinomycin Induced Hyperacetylation of Histone H3 and H4 in
the MDA-MB-231 Cells
The expression of p21 and increased histone hyperacetylation
have been previously linked to apoptosis, growth arrest and cellular
senescence. Therefore, we examined the acetylation profile of Histone H3
and H4 in MDA-MB-231 cells at 6, 24 and 48 hours with increasing
concentrations of Salinomycin. In figure 26, time course analysis showed
a gradual increase in acetylated Histones, H3 and H4. A marked overall
increase in the acetylation status of histone H3 and H4 was also detected
by immunofluorescence staining (fig. 27). Altogether, these results show
that Salinomycin induces acetylation of Histone H3 and H4.
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Figure 26. Western Blot Analysis of Ac-H3 and Ac-H4 Expression in
Salinomycin Treated MDA-MB 231 Cells. β-actin was used as loading
control.

Figure 27. Immunofluorescence Staining of Ac-H3 and Ac-H4 in MDAMB-231 Cells Treated with 10 and 25 µM Salinomycin for 24 hours. DAPI
was used as a nuclear stain.
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3.10 Combination of Salinomycin with Frondoside A or with 4Hydroxy-Tamoxifen

Enhanced

Cell

Death

and

Activation

of

Caspase3/7
Recently, frondoside A (Fr), a triterpenoid glycoside isolated from
the sea cucumber, Cucumaria frondosa, has been shown to inhibit
survival, migration, and invasion of MDA-MB-231 cells [138]. In vivo,
frondoside A strongly decreased the growth of MDA-MB-231 tumor
xenografts in athymic mice, without precipitating significant toxic sideeffects. Although frondoside A is not used as an anti-cancer drug, we
decided to investigate whether Salinomycin could sensitize MDA-MB-231
cells to this compound. We have chosen to use 1µM of frondoside A, a
concentration that induces 30% inhibition of cellular viability. Remarkably,
frondoside A potentiated the growth inhibitory effect of different
concentrations of Salinomycin (fig. 28).
We next examined the efficacy of Salinomycin (2.5-50 µM) in
combination with 4-Hydroxy-Tamoxifen (20 µM), the active metabolite of
tamoxifen, the breast cancer drug, in MCF-7 cells. Combined treatment
caused a significantly greater inhibition in cellular viability than treatment
with either drug alone (fig. 29) after 48 hours of treatment. Moreover, a
combination of Salinomycin with 4-Hydroxy-Tamoxifen significantly
increased the activation of Caspase 3/7, suggesting that apoptosis is
higher compared with treatment with either drug alone (fig. 30).
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Figure 28. Salinomycin Enhanced Cell Death Induced by Frondoside A in
MDA-MB-231 Cells.

Figure 29. Salinomycin Enhanced Cell Death Induced by 4 HydroxyTamoxifen in MCF-7 Cells.
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Figure 30. Salinomycin Induced Synergistic Apoptosis Against MCF-7
Cells. Fr represents frondoside A, Salino represents Salinomycin and 4HT represents 4-Hydroxy-Tamoxifen.
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DISCUSSION
Common cancer treatment drugs aim at inducing cell death and
apoptosis, which are considered prerequisites for preventing malignant
cell growth. Several studies have demonstrated that cellular senescence
can occur in vivo and may provide a critical barrier for cancer
development and cancer progression [139]. In fact, treatment of cancer
cell lines with different chemotherapeutic drugs induces irreversible
growth arrest associated with senescence like-phenotype [140, 141].
Indeed, induced-senescence appears to be a promising alternative
strategy for cancer treatment.
Our present work shows that (1) Salinomycin significantly
decreased viability of the wild-type p53 MCF-7 and T47D as well as
mutant p53 MDA-MB-231 human breast cancer cell lines in concentration
and time–dependent manners, and that (2) MDA-MB-231 cells respond
differently to low and high concentrations of Salinomycin. Our results
demonstrate that high concentrations of Salinomycin (25 and 50 µM)
induce G2 arrest, downregulation of survivin and activation of the
apoptotic signaling pathway resulting in the activation of Caspase 3/7 and
PARP cleavage. This finding is in agreement with previous reports
demonstrating that the anti-cancer effect of Salinomycin on different
cancer cell lines was due to its apoptosis-inducing activity [115, 118, 123,
142]. Interestingly, our results show for the first time that low
concentrations of Salinomycin (≤10µM) induce senescence in MDA-MB231 cells. We found that Salinomycin-treated MDA-MB-231 cells exhibited
markers of senescence including SA-β-galactosidase activity, changes in
52

morphology, cell cycle arrest, Histone H3 and H4 hyperacetylation and
elevated expression of the cyclin-dependent kinase inhibitor, p21. We also
report that Salinomycin enhanced the killing of the MCF-7 and MDA-MB231 cells by chemotherapeutic agents, 4-Hydroxy-Tamoxifen and
frondoside A, respectively.
We showed that data on the cell viability of MDA-MB-231
determined by CellTiter-Glo and Trypan Blue Exclusion were not superimposable even though they follow the same pattern i.e. growth inhibition
at lower concentrations and cell death at higher concentrations. CellTiterGlo Assay which is based on quantification of the ATP present showed
less effect on the viability of the MDA-MB-231 compared to the Trypan
Blue Exclusion Assay when the same concentration was used.
Interestingly, it has been reported that DNA-damaging agents such as
etoposide and temozolomide induce an ATP surge in cancer cells [143],
which explains the differences observed between CellTiter-Glo and
Trypan Blue Exclusion Assay in Salinomycin-treated MDA-MBA-231 cells.
In our study, we observed that at a concentration of 2.5 and 5 µM,
Salinomycin induced a G1 arrest at 24 hours and G2 arrest at 48 hours
post-treatment. Earlier reports have shown that low concentrations of 2.5
and 5 µM of Salinomycin also induced a G1 arrest in the MCF-7 and
Hs578T breast cancer cells after 24 hours of treatment [122, 123] which is
in agreement with our data on the MDA-MB-231 cells. However, no further
concentrations or time points were tested. Cyclin D1, a cyclin required for
G1 to S transition, was found to be reduced upon Salinomycin treatment
and could be the main cause for the G1 block. Our data also suggested
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that cell cycle arrest at the G2 phase might be mediated by the reduction
of cyclin B1. Moreover, the level of cyclin B1 at 5 µM Salinomycin seemed
to decrease at later times than cyclin D1 decreased. Interestingly,
Curcumin was also shown to induce a successive G1/S arrest at earlier
times and G2/M phase arrest at later time point in HOS cells [144]. The
exact mechanism by which cells undergo a transient G1 arrest followed by
a G2 arrest remains unclear. Our data also showed, for the first time, that
Salinomycin at higher concentration induced a robust G2 arrest confirmed
by cyclin B1 decrease and p(ser10) Histone H3. The cell cycle arrest data
is in agreement with the growth inhibition data shown by cell viability (fig 1,
5,6, 15) and colony growth assay (fig. 16). Interestingly, we found that the
CDK inhibitor p27, also a marker of G1 arrest, was downregulated during
the transient G1 arrest observed at 5 µM. This is not surprising as a report
by Yongxian and Miskimins showed that G1 arrest in MDA-MB-231 breast
cancer cells treated with metformin involves down regulation of cyclin D1
and requires p27 or p21 [145].
Inhibitor of Apoptosis Proteins (IAPs), which includes survivin,
represents a family of anti-apoptotic proteins that bind and inactivate
Caspase 3, 7 and 9 [146-148] and can modulate cell division and cell
cycle progression [149]. Survivin has been shown to be highly expressed
in most cancers, where it functions as an inhibitor of apoptosis. In breast
cancer, overexpressed survivin was shown to protect cells against
apoptosis induced by chemotherapeutic agents, such as Etoposide [150].
In consideration of the role of survivin as a custodian of cancer cell
survival, our results suggest that Salinomycin at high concentration might
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exert its cytotoxic anti-cancer effects at least partly via the downregulation of survivin.
Senescent cells are known to remain viable and metabolically
active, but are permanently growth arrested [151]. Growth arrest is
achieved and maintained in either G1 or G2/M stage of cell cycle, at least
through overexpression of specific cyclin-dependent kinase inhibitors such
as p16, p21 and p27 [139] [152-154]. Schwarze et al have previously
shown that p21 is more important in cell cycle arrest that is associated
with early senescence, while p16 appears to be important for maintaining
the senescence phenotype [152]. Senescence is triggered by DNA
damage to cells which respond via the induction of a group of genes
responsible for the development of the senescence phenotype [155]. The
decision of the cell to undergo either apoptosis or senescence is
dependent, at least in part, upon the magnitude of DNA damage caused
to cancer cells. Low levels of DNA damage may induce senescence
without activating the apoptotic pathway. Several studies reported that
many senescence inducing drugs generate DNA damage. In fact,
treatment of prostate cancer cells with high doses of doxorubicin, a DNAdamage inducing chemotherapeutic drug, leads to apoptosis, while a
lower dose of doxorubicin induces senescence [156]. Furthermore,
doxorubicin was shown to induce senescence in numerous cancer cell
lines, including those lacking p53 [157] .The same observation was made
when cisplatin [158], hydroxyurea [159] or bromodeoxy uridine [160] were
used.
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The expression of the cyclin-dependent kinase inhibitor p21 has
been implicated in chemotherapy induced cell cycle arrest in various
human cancers [152, 153, 161-163]. The contribution of p21 to cellular
senescence has been demonstrated by numerous studies [152-154]. In
fact, p21 has been found to be upregulated in senescent cells. Moreover,
forced overexpression of p21 was shown to be sufficient to induce cell
cycle arrest, and premature senescence in wild-type and mutant p53 cells
[155]. In line with this data, we reported that Salinomycin at concentrations
of ≤ 10 µM is able to induce maintained upregulation of p21 expression in
the MDA-MB-231 cells. Based on these data, we propose that induction of
senescence in Salinomycin-treated MDA-MB-231 breast cancer cells is
mediated, at least, partly through a p53-independent upregulation of p21
protein and does not involve p27 since, its expression decreased in a
time- and dose dependent manner (fig. 24).
It has also been reported that cellular senescence is associated
with

modifications

in

chromatin

structure

[156,

157].

Histone

hyperacetylation has been directly linked to the upregulation of p21 and
this activation can also occur independently of p53 [39]. Our data showed
that Salinomycin induced Histone H3 and H4 hyperacetylation. We have
also found that histone hyperacetylation correlated with a p53independent upregulation of p21 expression and growth inhibition in the
MDA-MB-231 cells. Our data suggest that Histone H3 and H4
hyperacetylation could be one of the mechanisms through which
Salinomycin exerts its anti-cancer activity, at least, in breast cancer.
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Recent studies reported that Salinomycin potentiates the anticancer activity of several DNA damage-inducing chemotherapeutic drugs
[121] as well as sensitizes cancer cells to radiation [122]. Salinomycin
was also shown to sensitize cancer cells to inhibitors of DNA replication
[120] and to antimitotic drugs [123]. Consistent with these reports, our
results show that Salinomycin indeed potentiates the anti-cancer activity
of two other drugs, namely frondoside A and the anti-estrogen 4-HydroxyTamoxifen in MDA-MB-231 and MCF-7 respectively.
In summary, our study is consistent with the model shown in figure
31, in which treatment with Salinomycin induces double strand breaks,
revealed by an accumulation of γH2AX. The magnitude of DNA damage,
which depends on the concentration of Salinomycin, determines the
response of the cells to this damage. We propose that the presence of
large amounts of DNA damage induced by high concentrations of
Salinomycin, MDA-MB-231 cells respond by triggering the apoptotic
signaling pathway through activation of Caspase 3/7 and cleavage of
PARP. In contrast, limited DNA damage caused by low concentrations of
Salinomycin triggers a rapid program of senescence which is mediated, at
least partly, through hyperacetylation of Histone H3 and H4 which
subsequently results in the upregulation of p21 expression.
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Figure 31. Hypothetic Model for the Differential Effect of Salinomycin in
MDA-MB-231 Breast Cancer Cells.
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CHAPTER 3: RESULTS AND DISCUSSION
Part II. Anti-Tumor Growth and Anti-Metastatic Activity of Origanum
majorana Extract on the Triple Negative Breast Cancer
3.12 O. majorana Extract Inhibited the Viability of the MDA-MB-231
Breast Cancer Cells
To examine the anticancer activity of Origanum majorana extract
(OME) on breast cancer cells, we first measured the effect of various
concentrations of the extract (0, 50, 150, 300, 450 and 600 µg/mL) on the
proliferation of the MDA-MB-231 breast cancer cell line (fig. 34). Our
results show that exposure of the MDA-MB-231 to OME decreased
cellular viability in a concentration- and a time-dependent manner. The
IC50 (producing half-maximal inhibition) was approximately 350 µg/mL at
24 hours and 400 µg/mL at 48 hours treatment. Observation of the OMEtreated MDA-MB231 cells under light microscopy also revealed that the
number

of

cells

decreased

when

the

concentration

increased.

Furthermore, as shown in figure 33, light microscopy observation of MDAMB231 cells treated with concentrations of 150, 300 and 450 and 600
µg/mL OME, underwent morphological changes characterized by a loss of
their epithelial morphology visible after 24 hours of treatment. Echinoid
spikes and cellular rounding, characteristics of apoptotic cells were also
observed.
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Figure 32. Inhibition of Cell Viability of MDA-MB-231 Cells by O.
majorana Extract.

Figure 33 . Micrograph of MDA-MB-231 Cells After 24 Hours Incubation
with Various Concentrations of OME.
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3.13 O. majorana Extract Lead to Mitotic Arrest and Apoptosis in
MDA-MB-231 Cells
The ability of an anticancer drug to affect cell cycle distribution can
provide information regarding its cytotoxic mechanism(s) of action. For
this reason, we investigated the effect of OME on cell cycle distribution
using flow cytometry. MDA-MB 231 cells were treated with the indicated
concentration of O. majorana for 24 hours and subjected to cell cycle
analysis. At a concentration of 150 µg/mL, OME caused an obvious G/2M
arrest of these cells (fig. 34). Indeed, the population of G2/M increased
significantly from 23 to 51.7% as the concentration of the OME increased
to 150 µg/mL, indicating that OME-treated MDA-MB-231 cells were
arrested in the G2/M phase. A slight increase in the sub-G1 population
(6.2%) was also observed by these concentrations indicating that a small
population of OME-treated MDA-MB-231 cells is undergoing cell death.
Interestingly, at higher concentrations of OME, flow cytometry analysis
revealed a dramatic increase in the apoptotic population (sub-G1 peak)
rising from 0.9% in the control group to 48.4% and 56.7% in cells treated
with 600 and 450 µg/mL, respectively (fg. 34).

To determine whether OME specifically induced cell cycle arrest at
mitosis or the G2 phase, we examined the phosphorylation status of
Histone H3 (Ser 10). Histone H3 is phosphorylated at serine 10 during
mitosis by aurora kinase and the phosphorylation status of H3 is
considered a marker of mitosis [132]. We therefore, investigated the
expression of p(ser10)H3 and found that treatments 150 and 300 µg/mL
of O. majorana significantly increased the phosphorylation level of Histone
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H3 (fig. 35, upper panel). This result indicates that OME induces mitotic
arrest of MDA-MB231 cells. Next, we investigated the mechanism of
OME-induced mitotic arrest. Accumulation of cyclin B1 is well known to
play an important role in G2/M transition. Knock-down of cyclin B1 with
siRNA produces cell cycle arrest predominantly in the G2 phase [133],
while an upregulation of cyclin B1 invokes mitotic arrest [134]. We,
therefore, investigated the protein level of cyclin B1 in OME-treated MDAMB-231 cells. We found that treatment with these concentrations of OME
leading to mitotic arrest, caused also an increase of cyclin B1 protein in
MDA-MB-231 cells (fig. 35, lower panel), suggesting that cyclin B1
accumulation might play a crucial role in OM triggered mitotic arrest.
Taken together, our findings reveal a differential concentration effect of
OME on cell cycle progression of MDA-MB 231 cells. Whereas, lower
concentrations of OME (150 and 300 µg/mL) induced a major mitotic
arrest with a slight increase in the apoptotic population, higher
concentrations (450 and 600 µg/mL) induced massive cell death by
apoptosis. The reduced cell viability observed in MDA-MB231 cells treated
with low concentrations of OME, is possibly due to a large extent to an
inhibition of cell proliferation rather than to cell death.
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Figure 34. Flow Cytometry Analysis Showing a G2/M Cell Cycle Arrest
Induced by O. majorana Extract in MDA-MB-231 Cells.
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Figure 32 . 42Western Blot Analysis of Phosphor(ser10)-H3, and Cyclin
B1 in OME Treated MDA-MB231 Cells.
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Apoptosis in OME-treated MDA-MB-231 cells was further examined
by measuring Caspase 3/7 activation in MDA-MB 231 cells treated with
various concentrations (300, 450 and 600 µg/mL) of OME after 24 hours
of treatment. A concentration- and time-dependent activation of caspase
3/7 was detected in treated cells (fig 36). Interestingly, cleavage of the
poly(ADP-ribose) polymerase (PARP) occurred only in cells treated with
higher (450 and 600 µg/mL), but not at lower concentrations (150 and 300
µg/ml) of OME (fig. 37). It is worth mentioning that at these lower
concentrations of OME, only a low apoptotic induction rate was observed
despite the detection of Caspase 3/7 activation.

Figure 36. Stimulation of Caspase 3/7 Activity in OME Treated in MDAMB-231 Cells.
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Figure 37. Concentration-Dependent Induction of PARP Cleavage in OME
Treated MDA-MB231 Cells.

3.14 Concentration-Dependent Regulation of Survivin Expression by
O. majorana Extract
Survivin, a member of the inhibitor of apoptosis protein (IAP) family,
plays an important role in both the regulation of cell cycle and the
inhibition of apoptosis. Survivin levels increase in the G2/M phase
conferring resistance to apoptosis to the G2/M arrested cells. However, a
decrease in survivin levels sensitizes the cells to apoptosis. Several
studies have reported that survivin exerts its negative effect on apoptosis
by inhibiting the activity of Caspase 3, 7 and 9. Therefore, we examined
the possible involvement of survivin in cell cycle arrest and apoptosis
triggered by OME. We analyzed, by Western blotting, the expression of
survivin in response to various concentrations of OME after 24 hours of
treatment. Interestingly, we observed a differential concentration-effect of
OME on survivin expression in the MDA-MB-231 cells (fig. 38). We found
that low concentrations of OME led to a substantial increase in the level of
survivin, while higher concentrations caused a drastic decrease of survivin
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(99%). Based on these results, we concluded that OME exerts a
concentration-dependent

effect

on

MDA-MB-231

cells.

Low

concentrations of OME induced a mitotically arrested cells accompanied
by survivin upregulation which, in turn, conferred resistance to cell death
to this population of cells, probably by inhibiting the activity of Caspase 3/7
which was monitored by the absence of PARP cleavage at these
concentrations.

Treatment

of

MDA-MB-231

cells

with

higher

concentrations of OME caused a dramatic decrease in survivin expression
and consequently sensitized MD-MB-231 cells to apoptosis.

Figure 38. Western Blot Analysis Showing A differential Effect on Survivin
Expression by Different Concentrations of OME in MDA-MB-231 Cells.
3.15 O. majorana Extract Activates the Extrinsic Pathway for
Apoptosis via an Upregulation of TNF-α and Activation of Caspase 8
Having shown that OME induces the activation of the effector
Caspases 3/7, we looked at the activity of the initiator caspases of the
extrinsic and intrinsic cell death pathway, namely Caspase 8 and Caspase
9, respectively. Surprisingly, no Caspase 9 activation was detected in
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response to various concentrations of OME after 24 hours of treatment (fig
39). On the other hand, caspase 8 activity increased in a concentrationdependent manner in response to OME treatment (fig 39). This result
demonstrates that the apoptotic effect of the extract on MDA-MB-231 is
dependent on caspase 8 activity, which implicates only the extrinsic cell
death pathway since no caspase 9 activation was observed. After showing
that the extrinsic cell death pathway is implicated in OME-dependent
apoptosis, we were then interested in determining how this pathway is
activated by OME. We determined the changes in the expression level of
the Tumor Necrosis Factor Alpha (TNF-α) in response to OME after 24
hours of treatment. Western blot analysis revealed a clear increase in the
level of TNFα in MDA-MB-231 cells in response to OME treatment (fig.
40).

The

upregulation

of

TNF-α

was

further

confirmed

by

immunofluorescence assay (fig 41). Even though we have shown that
OME exerts its effect via the activation of the extrinsic pathway of cell
death, we cannot rule out, at this stage, the possibility of OME-dependent
apoptosis could also be triggered by another mechanism.
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Figure 39. O. majorana Induced Apoptosis by Activation of Caspase 8
and but not Caspase 9 in MDA-MB-231 Cells.
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Figure 40. Western Blot Analysis Showing An increase in Cellular TNF-α
Protein in the MDA-MB-231 Cells Treated with OME.
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Figure 41. Immunofluorescence Staining for TNF-α in OME Treated
MDA-MB- 231 Cells.

3.16 O. majorana Lead to Depletion of Mutant p53 in MDA-MB-231
and Upregulation of p21WAF1/CIP1
Next, we tested the effect of OME on the expression of the tumor
suppressor p53 in MDA-MB-231. Toward this aim, cells were treated with
various concentrations of OME and the protein level of the mutant p53
was determined. We found that low concentrations of 150 and 300 µg/mL
of OME led to a slight increase in the protein level of mutant p53 (fig. 42,
upper panel). Most importantly, Western blotting analysis revealed
apoptotic concentrations (450 and 600 µg/mL of OME) lead to almost
complete depletion of mutant p53 in MDA-MB-231 cells. This result is a
potentially important finding because of the role of mutant p53 protein in
human cancers. Because mutant p53 renders cancer cells more resistant
45

to anti-cancer drugs, abolishing mutant p53 may therefore offer a
promising approach for cancer prevention and therapy.

Because p21 protein has been reported to inhibit growth and
apoptosis, we investigated whether the growth inhibition mediated by low
concentrations (150 and 300 µg/mL of OME) was also associated with an
induction of p21. Western blotting showed an upregulation of p21 protein
with at least 2.5 fold increases in cells treated with low concentrations of
OME, while little or no effect on p21 expression was observed with higher
concentrations of OME (fig. 42, lower panel). Based on that, we can
postulate that p21 upregulation contributes, at least partially, to the cell
cycle arrest observed with lower concentrations, while it has little or no
role in cell death occurring at higher concentrations of OME.

.
Figure 42. Western Blot Analysis Showing Expression Levels of Mutant
p53 and p21 in O. majorana Treated MDA-MB-231 Cells.
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3.17 O. majorana Extract Induced Hyperacetylation of Histone H3 and
H4 in the MDA-MB 231 Cells
Previously,

expression

of

p21

and

increased

histone

hyperacetylation has been linked to apoptosis and to growth arrest.
Therefore, we examined the acetylation profile of histone H3 and H4 in
MDA-MB-231 in response to treatment for 24 hours to increasing
concentrations of OME. As shown in figure 43, the time course analysis
showed a gradual increase in acetylated histones, H3 and H4. A marked
overall increase in the acetylation status of Histone H3 and H4 was also
detected by immunofluorescence staining (fig 44). Altogether, these
results showed that OME induced hyperacetylation of Histone H3 and H4.
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Figure 43. Western Blot Analysis Showing Protein Levels of Ac-H3 and
Ac-H4, Extracted from OME Treated Cells. β-actin was used as loading
control.
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Figure 44. Immunofluorescence Staining of Ac-H3 and Ac-H4 in MDAMB231 Cells Treated with OME for 24 Hours. DAPI was used as a nuclear
stain.
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3.18 O. majorana Induced Activation of γH2AX, a Marker of Double
Strand Breaks, in MDA-MB-231 Cells
We sought to investigate whether OME induced DNA damage in
MDA-MB-231 cells. For this purpose, MDA-MB 231 cells were cultured for
6 and 24 hours in a complete media containing either ethanol (control) or
increasing concentrations of OME (75, 150, 300, 450 and 600 µg/mL).
DNA damage was determined by measuring the levels of phosphorylated
H2AX (γH2AX) after 6 and 24 hours of treatment of the MDA-MB-231 cells
with OME. Western blot analysis revealed a time-and a concentrationdependent increase in the levels of γH2AX in response to OME treatment
(fig 45), indicating an accumulation of double strand breaks in these cells.
The increase in DNA damage was also assessed by immunofluorescence
staining of γH2AX in cells treated with 150, 300 and 450 µg/mL OME for
24 hours. Figure 47 clearly shows a concentration-dependent increase of
γH2AX foci in response to OME. Since the activation of γH2AX occurred
as early as 6 hours, a time in which no cell death or Caspase 3/7
activation was observed (fig. 46), this rules out the possibility that the
resulting DNA damage is a consequence of DNA fragmentation resulting
from caspases' activities and further confirms the potential of this OME
extract to induce double strand DNA breaks in a concentration-dependent
manner.
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Figure 45. Western Blot Analysis of Phosphor-H2AX (Ser 139) in MDAMB231 Cells Exposed to OME.
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Figure 46. Immunofluorescence Staining for γH2AX in OME Treated
MDA-MB 231 Cells.
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Figure 47. Caspase 3/7 Activation in OME Treated MDA-MB-231 Cells
After 6 Hours.
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3.19 O. majorana Inhibited Colony Growth of MDA-MB-231
To further confirm the inhibitory potential of O. majorana on MDAMB 231 cells, we sought to determine if OME could inhibit the further
growth of already formed MDA-MB-231 colonies. For this purpose, MDAMB-231 cells were first allowed to grow and form visible colonies in the
absence of treatment. After 14 days of growth, colonies were incubated
with ethanol as a control, and with OME, and allowed to grow for one
more week. Figure 48 shows that the size of the ethanol-treated (control)
colonies kept growing compared to the size of the two week colonies;
more large colonies were obtained in the three week plate, while fewer
small colonies were counted, indicating that small colonies became larger
in size. Interestingly, OM treated colonies showed regression in colony
size compared to the two week colonies. In OM-treated plates, the
number of large size colonies counted was fewer than that obtained in the
two week plate, while the number of small colonies was significantly
greater, suggesting size regression in the large colony induced by OME.
This result along with the viability and flow cytometry data confirm the anticancer effect of OME on triple negative mutant p53 MDA-MB-231 breast
cancer cells.
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.
Figure 48. Inhibition of Colony Growth by O. majorana Extract.
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3.20 O. majorana Attenuated the Migration Ability of the MDA-MB-231
Breast Cancer Cells
As cell migration plays a crucial role in tumor metastasis, we
sought to investigate whether OME affects the migration behavior of MDAMB-231 cells. We first measured the migration ability of these cells by
using a wound-healing migration assay. For this purpose, we performed
the test with concentrations of OME and periods of treatment that were
previously shown to be non-cytotoxic to the MDA-MB-231. As shown in
figure 49, OME treatment significantly inhibited wound healing cellular
migration of MDA-MB-231 cells in a concentration-dependent manner.
The ability of OME to inhibit the migration of MDA-MB-231 cells was also
measured by using the Boyden Chamber Transwell Assay. For this
purpose, MDA-MB-231 cells were seeded in the upper wells with or
without 300 µg/mL OME. As shown in Figure 51 and 52, the number of
OME-treated cells that migrated to the lower chamber, after 6 hours of
treatment, was significantly reduced approximately three fold compared to
the number of control cells. Cell viability of the OME-treated cells at the
concentrations and time tested was not affected (fig. 50) thus confirming
that the inhibitory effect on the MDA-MB-231 cells motility was not due to
the cytotoxic effect of OME. Taken together this confirms the inhibitory
effect of OME on the migration potential of MDA-MB-231 cells.

22

Figure 49. Wound Healing Assay Showing that OME Inhibited the
Migration of MDA-MB-231 Breast Cancer Cells in Dose-Dependent
Manner.
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Figure 50. Cell Viability After Incubation of MDA-MB-231 Cells with OME
For 10 Hours.

Figure 51. Boyden Chamber Transwell Assay Indicating that OME
inhibited the Migration of MDA-MB-231 Cells.
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Figure 52. Quantification of Migrated MDA-MB-231 Cells.

3.21 O. majorana Promoted Cell-Cell Aggregation and Induced ECadherin Upregulation in MDA-MB-231 Cells
Lost capacity for homotypic adherence is also associated with
cancer cell metastasis. To determine whether OME would affect the cellcell adherence behavior of MDA-MB 231, cell aggregation assay was
conducted on a control and OME-treated cells. We found that OME
significantly increased the ability of MDA-MB-231 cells to form cell
aggregates visible and as early as 30 minutes post-treatment (fig. 53). It is
known that loss of E-cadherin expression promotes tumor progression
and metastasis while its overexpression prevents the invasion of tumor
cells. We therefore sought to examine the expression of E-cadherin in
MDA-MB-231 cells in response to OME exposure. We first examined the
protein level of E-cadherin in MDA-MB-231 cells treated with and without
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OME. As shown in figure 54, OME induced a significant increase of Ecadherin protein in a concentration-dependent manner. This increase in Ecadherin expression was further confirmed by immunofluorescence
staining (fig. 55). The expression of E-cadherin was mostly detected at
cells junctions.
Next we determined whether the effect of OME on E-cadherin
expression was mediated through transcriptional regulation. Toward this,
transcription activity was measured in cells transfected with a Luciferase
Reporter gene containing E-cadherin promoter and treated with and
without OME. As shown in figure 56, OME induced a concentrationdependent increase in the luciferase activity, thus indicating that OME
positively regulates the expression of E-cadherin at the transcriptional
level. Taken together, the data clearly show that E-cadherin is upregulated
by OME and further suggests that the expression of this protein could
account for the inhibition of cellular migration and invasion.

Figure 53. Photograph Under Phase-Contrast Microscope
Magnification) Showing Aggregated Cells After OME Treatment.
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(x100

Figure 54. Western Blot Analysis of E-cadherin Expression in OME
Treated MD-MB-231 Cells.

Figure 55. Immunofluorescence Staining for E.cadherin in OME Treated
MDA-MB 231Cells. DAPI was used as a nuclear stain.
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Figure 56. E. cadherin Promoter Activity Following Transfection with A
Luciferase Reporter Gene Containing E-cadherin Promoter in MDA-MB231 Cells.
3.22 O. majorana Inhibited Invasive Capacity of MDA-MB-231 Cells
Next, we examined the invasive potential of MDA-MB-231 cells in
the Matrigel-coated Boyden Chamber in the absence, or presence, of 150
µg/mL OME. The number of OME-treated cells that has passed through
the Matrigel coated membrane was markedly reduced by 55% (fig. 57,
and 58), indicating that OME can inhibit the invasive ability of the MDAMB-231 cells.
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Vehicle

150 µg/mL (OME)

Figure 57. O. majorana Inhibited the Invasive Activity of MDA-MB-231
Cells.

Figure 58. Quantification of Invaded MDA-MB-231 into the Matrigel.
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3.23 O. majorana Suppressed the Expression and the Activity of
MMP-2 and MMP-9 and downregulated uPAR in MDA-MB-231 Cells
Matrix metalloproteinases (MMP) -2 and -9, among other MMPs,
are known to play an important role in breast cancer cell invasion and
metastasis. To test whether O. majorana inhibits breast cancer cell
invasion by affecting the expression of MMP-2 and MMP-9, we decided to
examine the expression levels of MMP-2 and MMP-9 proteins in a
conditioned medium using OME-treated MDA-MB-231 cells. The protein
level of MMP-2 and MMP-9 (fig. 59) were found to be significantly reduced
in response to OME treatment. RT-PCR analysis also revealed that the
MMP-2 and MMP-9 mRNA level was reduced in MDA-MB-231 cells upon
treatment with OME (fig. 60) indicating that OME can inhibit the
transcription of MMP-2 and MMP-9 genes in these cells.

Figure 59. Effects of OME on the Secretions of MMP-2 and MMP9 in the Collected Conditioned Medium of OME Treated MDA-MB231 Cells.
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Figure 60. RT-PCR Analysis of the mRNA Levels of MMP-2 and MMP-9
in MDA-MB-231 Cells Treated with OME for 24 Hours. GAPDH was used
as an internal control.

Then, we decided to examine the effect of OME on the activity of
MMP-2 and MMP-9. MDA-MB-231 cells were treated with 150 and 300
µg/mL OME for 24 hours in serum free DMEM, the media was collected,
concentrated and tested for MMP2 and MMP-9 activity by using gelatin
zymography. As shown in figure 61, MMP-2 and MMP-9 activities were
significantly reduced in response to OME treatment. Altogether, our
results showed that OME significantly inhibits both, the expression and the
activities of MMP-2 and MMP-9.
The Urokinase Plasminogen Activator (uPA) and its receptor
(uPAR) were also shown to play a crucial role in breast cancer cell
invasion and metastasis. Therefore, we examined whether OME also
alters the expression of uPAR. Western blot analysis clearly shows that
612

the expression level of uPAR decreased markedly in OME-treated MDAMB-231 cells (fig. 62).

Figure 61. Activities of MMP-2 and MMP-9 in OME Treated MDA-MB
231 Cells.

Figure 62. Western Blot Analysis of uPAR Expression in OME Treated
MD-MB-231 Cells. β-actin is used as loading control.
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3.24 O. majorana Decreased Adhesion of MBA-MB-231 to HUVEC and
downregulated the Expression of ICAM-1 in Breast Cancer Cells
The attachment of tumor cells to endothelial blood vessels is also a
crucial event in the process of metastasis. The effect of OME on MDAMB-231 cell adhesion to TNF-α stimulated HUVECs was then investigated
by co-incubating both cell types for 1 hour with, and without various
concentrations of OME. Figure 24A shows that OME significantly inhibited
the adhesion of MDA-MB-231 cells to HUVECs in a concentrationdependent manner.
Also, because the intercellular adhesion molecule (ICAM)-1, has
been shown to play an important role in the adhesion of cancer cells to
endothelial cells and therefore in metastasis, we sought to examine
whether OME affects the expression of this adhesion molecule in MDAMB-231 cells. Toward this aim, cells were treated with various
concentrations of OME and the protein level of the ICAM-1 was
determined by Western blotting. As it is shown in figure 64, the level of
ICAM-1 protein decreased in a concentration-dependent manner in OMEtreated MDA-MB-231 cells. Taken together, our results suggest that OME
exerts an inhibitory effect on the adhesion of MDA-MB-231 cells to
HUVEC and that this effect is associated with downregulation of ICAM-1
protein.
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Figure 63. Inhibition of Adhesion of MDA-MB-231 Cells to HUVEC by O.
majorana.

Figure 64. Western Blot Analysis of ICAM-1 Expression in OME Treated
MD-MB-231 Cells. β-actin is used as loading control.

3.25 O. majorana Inhibited Transendothelial Migration of MDA-MB231 Through TNF-α-Stimulated HUVECs
Since the migration of tumor cells through the vascular endothelium
is another crucial event in the metastasis process, we used the
Transendothelial Migration Assay to investigate the effect of OME on the
ability of MDA-MB-231 cells to migrate across a monolayer of endothelial
(HUVEC) cells. As seen in figure 65, the transendothelial migration of
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OME treatment through the monolayer of HUVEC was significantly
reduced by the treatment with OME in a concentration-dependent manner.

Figure 65. O. majorana Inhibited Migration of MDA-MB-231 Cells A cross
Monolayer of TNF- α Activated HUVECs.

3.26 O. majorana Suppressed VEGF Production in HUVECs and
MDA-MB-231 Cells
Tumor growth and metastasis critically depend on angiogenesis.
VEGF, a pro-angiogenic growth factor, has been shown to play an
important role in this process. Thus, we investigated the effect of OME on
the production of VEGF by both the MDA-MB-231 and endothelial cells
(HUVEC) with, and without, the presence of TNF-α. We first examined the
effect of OME on basal expression levels of VEGF in MDA-MB-231 cells.
Cells were grown with various concentrations of OME, the conditioned
medium was collected and the level of VEGF measured by ELISA. Data
shown in Figure 66 revealed that treatment with 300 and 450 µg/mL OME
for 24 hours markedly reduced the secretion of VEGF by MDA-MB-231
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cells. VEGF levels dropped from 1300 pg/mL in the control to 800 and 400
pg/mL respectively. To further confirm the inhibition of VEGF production
in breast cancer cells, we measured the level of VEGF in MDA-MB-231
cells that were first treated with various concentration of OME and then
stimulated with TNF-α. As shown in figure 67, the production of VEGF was
enhanced in TNF-α - stimulated (2600 pg/mL) compared to vehicle-treated
(1500 pg/mL) MDA-MB-231 cells. However, VEGF production was
significantly reduced in a concentration-dependent manner by OME (fig.
67). Next, we examined VEGF production in HUVECs. As expected, a
HUVEC cultured in the absence of TNF-α produced low level of VEGF (20
pg/mL), while in the presence of TNF-α, VEGF production increased to
approximately 120 pg/mL (fig. 68). Exposure of HUVEC to OME also led
to a concentration-dependent suppression of VEGF production (fig. 68).

Figure 66. Quantification of Basal Level of VEGF Secretion in
Conditioned Medium from Vehicle or OME Treated MDA-MB-231 Cells.

612

Figure 67. Quantification of VEGF Secretion in TNF-α Induced MDA-MB231 Cells Cultured in Presence of Vehicle or Indicated Concentrations of
OME.

Figure 68. Quantification of VEGF Secretion in TNF-α Induced HUVECs
Cultured in Presence of Vehicle or Indicated Concentrations of OME.
.
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3.27 O. majorana Inhibited Phosphorylation of IκB; Downregulated
Nuclear Level of NFB
The NFB signaling pathway is known to regulate the expression of
various genes involved in tumor cell invasion. To investigate the effect of
OME on the activation of the NFB signaling pathway, we first examined,
by Western blotting, the phosphorylation status of IB in OME-treated
MDA-MB-231 cells. We found that OME drastically inhibited the
phosphorylation of IB (fig. 69). Moreover, we found that OME reduced
the level of nuclear NFB remarkably (fig. 70). Taken together, the data
clearly indicates the OME exerts its effect at least partly through an
inhibition of the NFB signaling pathway.

Figure 69. Western Blot Analysis of the Phosphorylation Status of IκBα.
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Figure 70. Western Blot Analysis of the Nuclear p65 (NFB). β-actin
(loading control) proteins.

3.28 O. majorana Reduced Nitric Oxide (NO) production in MDA-MB231 Cells
Nitric oxide (NO) signaling has also been shown to promote breast
tumor growth and metastasis by altering the expression of genes
implicated in cellular migration, invasion and angiogenesis [164-166]. To
test whether OME could affect the level of NO, the amount of nitrate/nitrite
production was determined by ELISA in vehicle and OME-treated MDAMB-231 cells. Results shown in figure 71 clearly show that OME
decreased NO production in a concentration-dependent manner in MDAMB-231 cells, thus suggesting that OME could also exert its antimetastatic effect by modulating the level of NO in breast cancer cells.
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Figure 71. Quantification of NO Levels in OME Treated MDA-MB-231
Cells.

3.29 O. majorana Inhibited Tumor Growth and Metastasis in Chick
Embryo Tumor Growth and Metastasis Assay
To further confirm the in vitro anti-breast cancer activities of O.
majorana, we decided to investigate its effect on tumor growth in vivo by
using the chick embryo model. MDA-MB-231 cells were grafted on the
chorioallantoic membrane (CAM) and formed tumors were treated every
48 hours with vehicle, colchicine (2 µM) or increased concentrations of
OME (300 and 450 µg/mL). At E19, tumors were recovered from the
upper CAM and weighed. As it is shown in figure 72 and 73, OME
significantly inhibited tumor growth compared with the control treatment. In
fact, concentrations of 300 and 450 µg/mL OME led to reduced tumor
growth by 55 and 60% respectively. A similar effect (65% inhibition) was
obtained with 2 µM colchicine. Toxicity was evaluated by comparing the
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number of dead embryos in OME-treated and control (vehicle-and
colchicine-treated) embryos. We found that OME showed no toxicity to the
embryo (data not shown).
We next assessed for the ability of OME to inhibit metastasis by
counting the number of nodules in the lower CAM in vehicle, colchicine
and OME treated tumors. An average of 6.6 nodules were counted in the
lower CAM of vehicle-treated chick embryo, while an average of only 1.1
nodules were counted in 300 and 450 µg/mL OME-treated embryos (fig.
74). The data clearly demonstrates that OME could efficiently inhibit
breast tumor growth and metastasis in vivo.

Figure 72. Anti-tumor Growth of O. majorana on Breast Tumor in a
Chick Embryo Chorioallantoic Membrane Model System.
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Figure 73. Quantification of Tumor Weight in Vehicle, Colchicine and
Indicated Concentrations of OME Treated Chick Embryo.

Figure 74. Anti-Metastatic Effect of O. majorana. Quantification of Nodules
Observed in the Lower CAM of Chick Embryo Treated with Vehicle,
Colchicine or OME.
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DISCUSSION
Common cancer treatment drugs aim at inhibiting cell cycle
progression

and

at inducing cell death

and

apoptosis.

Cancer

chemoprevention through these two events (cell cycle arrest and
apoptosis) has been reported for several natural compounds [21, 167-70].

In the present study, we have shown that extract of an ethanolic
fraction of Origanum majorana inhibited the proliferation of mutant p53
triple negative breast cancer (TNBC) cell line, MDA-MB-231. We have
also demonstrated that OME induces a differential concentrationdependent effect on these cells. OME induces a cell cycle arrest at the
G2/M phase and more precisely a mitotic arrest at low concentrations.
This finding is supported by a body of evidence: (i) an increase in the level
of p(ser10)H3, a mitotic marker, and (ii) an increase of cyclin B1 protein
level, whose upregulation was reported in several mitotically arrested
cells. We have also shown that cell cycle arrest correlates with an
upregulation of the CDK inhibitor p21 and the anti-apoptotic protein,
survivin. At high concentrations, however, OME induced a massive
apoptosis demonstrated by a dramatic increase in the sub-G1 population.
We have demonstrated that OME exerts its apoptotic effect by activating
the cell death extrinsic pathway, at least partially, via the activation of
TNF-α. We have also shown that OME-induced apoptosis is mediated by
an increase in DNA damage, revealed by an upregulation of γH2AX,
severe depletion of the mutant p53 and survivin proteins from the treated
cells.
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The process of apoptosis can be induced either by the extrinsic
pathway which involves signaling from death receptors at the cell surface
or by the intrinsic mitochondria-mediated pathway [171]. Activation of the
death receptor-mediated apoptosis requires the interaction of ligands such
as TNF-α and Fas with their transmembrane receptors [172]. The ligandreceptor interaction leads to the activation of the effector Caspase 8,
which in turn activates the effector Caspase 3 directly and/or through
mitochondria [173]. The mitochondria-mediated apoptosis pathway is
associated with permeabilization of the mitochondria outer membrane,
reduced mitochondrial membrane potential (Δψm), change in expression
of the anti-apoptotic Bcl2 family members, such as Bcl2 and Bcl-XL and
the pro-apoptotic members such as Bax and Bak lead to the formation of
apoptosome, activation of Caspase 9 and consequently activation of
caspase 3 [174]. Intrinsic- and extrinsic-pathways activated Caspase 3,
cleave PARP, thus resulting in apoptosis [175]. In the present study, we
showed that OME induced a TNF-α-mediated extrinsic apoptotic pathway.
A TNF-α receptor was activated at 24 hours and induced downstream
signaling such as Caspase 8, caspase 3, and PARP cleavage. On the
other hand, OME did not induce mitochondria-mediated apoptotic pathway
since no change in the BAX/Bcl2 ratio or activation of Caspase 9 were
detected. We suggest that OME induces apoptosis solely through a TNF-α
activated signal pathway in MDA-MB-231 cells.

Studies have reported that DNA damage is one of the molecular
events associated with cell cycle arrest and apoptosis. Indeed, many anticancer drugs have been shown to induce DNA damage [176] [177].
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Moreover, cancer cells are reported to be more susceptible than normal
cells to DNA damaging agents [178], therefore there is a growing interest
in dietary phytochemicals that possess DNA-damaging activity. In the
present study we showed that OME elicited DNA damage measured by an
increase in a concentration-dependent manner of the marker of DNA
damage, γ-H2AX, after treatment with OME for 6 or 24 hours. The
differential response to the different concentrations of OME (G2/M arrest
and/or apoptosis), may be partially mediated by the extent of DNA
damage that occurs within the genome. Low levels of DNA damage may
trigger recruitment of DNA repair complexes, expression of anti-apoptotic
and survival proteins leading to arrested cell cycle until the genotoxic
lesions are repaired. In this case, survival proteins such as survivin get
activated in order to maintain the viability of G2/M arrested cells. On the
other hand, when genomes are overwhelmed by DNA damage, cells are
eliminated by apoptosis [179, 180]. In this study, we have found that high
concentrations of OME triggered high level of DNA damage to the
genome, causing cell to enter apoptosis. Our data suggest that Origanum
majorana possess a genotoxic effect on MDA-MB-231 cells. At this stage,
the mechanism(s) by which OME induces DNA damage remain(s)
unknown, and certainly deserves further study.

Inhibitor of apoptosis proteins (IAPs), which includes survivin,
represents a family of anti-apoptotic proteins that bind and inactivate
active Caspase 3/7 [146, 147] and Caspase 9 [148] and can modulate cell
division and cell cycle progression [149].
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Interestingly, survivin has no effect on Caspase 8 activity. Survivin has
been shown to be highly expressed in most cancers, where it functions as
an inhibitor of apoptosis. In breast cancer, overexpressed survivin was
shown to protect cells against apoptosis induced by chemotherapeutic
agents, such as etoposide [146]. Based on these reports, survivin proteins
represents an attractive target of particular importance in cancer therapy
at large and in breast cancer therapy in particular. In consideration of the
recognized role for survivin as a custodian of cancer cell survival, our
results suggest that OME might exert its cytotoxic anti-cancer effects, at
least partly via the downregulation of survivin. In our study, we have
shown

that

survivin

expression

is

differentially

regulated

in

a

concentration-dependent manner by OME. Lower concentrations of OME
induced an upregulation of survivin which causes cells to arrest the cell
division and to resist apoptosis by inhibiting the cell death program. In
fact, we showed that in these arrested cells, PARP cleavage was not
detected despite the activation of Caspase 3/7. This effect might be
mediated by the inhibition of active 3/7 by the upregulated survivin.
Survivn function could also account for the mitotic arrest induced by OME.
In fact, survivin, has also been shown to be required for mitotic arrest of
HeLa cells induced by the anti-cancer drug UCN-01 [181].

The tumor suppressor protein, p53 is found to be mutated in about
50% of human cancers [150]. Mutant p53 is reported to play a key role in
cancer cells resistance to certain anti-cancer drugs and thus is considered
as a potential cancer-specific target for pharmacologic interventions [182],
[183]. Studies have shown that inhibition of mutant p53 by RNA
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interference sensitizes cancer cell to cell death by chemotherapeutic
agents [184]. Wang et al. 2011, showed that the naturally occurring
isothiocyanate (ITC) phenetyl isothiocyanate (PEITC), derived from the
watercress plant, and the synthetic ITC, 2,2-di phenetyl isothiocyanate
selectively deplete mutant, but not the wild-type p53, and induce
apoptosis in many cancer cells, including MDA-MB-231 breast cancer
cells [185]. Here, we showed that OME led to a dramatic decrease in the
mutant p53 level in MDA-MB-231 cells. As such, mutant p53 depletion
may be an important target for chemoprevention and therapy by O.
majorana for TNBC.

Increase in the expression of the cyclin-dependent kinase inhibitor,
p21 has been shown to augment G2/M arrest via a p53-independent
mechanism in human breast cancer [186]. In most cases, growth arrest
was found to be associated with apoptosis. In this study, we showed that
low concentrations of OME treatment led to G2/M arrest without significant
increase in cell death after 24 hours treatment. Histone hyperacetylation
has been demonstrated to be directly linked to the upregulation of p21 and
this activation can also occur independently of p53 [187]. Moreover,
histone hyperacetylation was also shown to be associated with growth
suppression and apoptosis. Our data showed that OME induced histone
H3 and H4 hyperacetylation in MDA-MB-231 cells, suggesting that the
anti-breast cancer effects of OME were at least partly mediated by
Histone H3 and H4 hyperacetylation by regulating the expression of the
genes controlling these two events. The mechanism by which OME
induces histone hyperacetylation might involve a Histone Deacetylase
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Inhibitor (HDI) activity. Interestingly, the plant, O. majorana, contains
luteolin, a dietary flavonoid with HDI activity [98]. In fact, luteolin was able
to decrease the viability of lung, colon, liver and breast cancer cells and
induce hyperacetylation of histone H3 and H4 [188]. In light of this, we
conclude that the Histone hyperacetylation induced by OME is involved
with the HDI activity of luteolin. We are currently undertaking further
investigations to better understand the mechanism(s) by which OME
induces Histone hyperacetylation.

In conclusion, our data is consistent with the model shown in figure
75 which shows the concentration-dependent differential effect of O.
majorana extract on mutant p53, triple negative MDA-MB-231 cells. At low
concentrations, OME induced a mitotic arrest associated with low level of
DNA damage (75, thin arrow), upregulation of the CDK inhibitor p21 and
the inhibitor of apoptosis, survivin. We believe that these events along
with other yet to be identified events contribute to the cell cycle arrest. In
addition we also propose that, at these concentrations, survivn is also
implicated in the blockage of the TNF-mediated apoptosis pathway, by
directly inhibiting the activity of the active Caspase 3. On the other hand,
high concentrations, OME induce massive apoptosis via the activation of
the TNF-α extrinsic pathway which is associated with high level of DNA
damage (fig. 75, thick arrow) and almost complete depletion of the mutant
p53 and surviving proteins from these cells. Our findings provide the first
instance of a potential role for OME as an anti-breast cancer agent in vitro
which certainly deserves more attention and further exploration to identify
novel compounds for breast cancer.
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Figure 75. Proposed Mechanisms of Action of O. majorana on MDA-MB231 Cells.
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Tumor invasion and metastasis is a multistep process involving cell
adhesion, proteolytic degradation and migration through the ECM and
angiogenesis. Common cancer treatment drugs aim at blocking cell cycle
progression, inducing cell death and/or inhibiting tumor migration and
invasion. Cancer chemoprevention through these events has been
reported for several natural compounds [21] [167-170]. Nowadays, there
is a growing interest in combination therapy using multiple anti-cancer
drugs affecting several targets/pathways. Herein, we demonstrate for the
first time that O. majorana, at non-cytotoxic concentrations, possesses
potent anti-metastatic properties against the highly invasive triple negative
breast cancer cell line, MDA-MB-231. In fact, O. majorana efficiently
inhibited the migratory abilities and induced homotypic aggregation of
MDA-MB-231 cells, associated with an upregulation of E-cadherin
expression. We also showed that O. majorana not only decreased the
adhesion of MDA-MB-231 to HUVECs as well as their transendothelial
migration, but also inhibited the secretion of the pro-angiogenic factor
VEGF from both endothelial and breast cancer cells. In addition we
demonstrate that O. majorana suppressed the expression and the
activities of MMP-2 and MMP-9 and downregulated the expression of
uPAR and ICAM-1. O. majorana also blocked IB-α/NFB and reduced
Nitric Oxide (NO) production, both signaling events involved in cancer cell
invasion. Moreover, we demonstrated that O. majorana significantly
inhibited tumor growth and metastasis in vivo in a chick tumor growth
assay.
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It is well known that disruption of cell-cell adhesion during cancer
progression is the initial stage required for the acquisition of invasive
properties. Decreased cell-cell adhesion in cancer cells is often
characterized by diminished expression of E-cadherin. Indeed, Ecadherin, a calcium-dependent, cell adhesion molecule, is considered as
a tumor suppressor in breast cancer [189]. A decrease in E-cadherin
expression is a critical and necessary event required in the disruption of
cell-cell adhesion and thus for the acquisition of invasive phenotype of
various tumors including breast cancer. In fact, downregulation or loss of
E-cadherin during cancer progression is associated with aggressive
behavior by the tumor and a poor prognosis for the patient [190].
Conversely, expression of E-cadherin can lead to a reduced progression
and invasion of breast cancer cells [191]. In the present study, we
demonstrated that O. majorana inhibited cell migration and promoted
homotypic cell-cell aggregation and induced overexpression of E-cadherin
in the MDA-MB-231 cells. We postulate that O. majorana exerts its antimigratory effect on breast cancer cells, at least partly, through reactivation
of the expression of E-cadherin gene. In fact we showed that OME was
able to induce transactivation of E-cadherin promoter in transfected cells
(Fig. 3D). Induction of E-cadherin expression promotes then homotypic
aggregation of OME-treated MDA-MB-231 cells. Thus, E-cadherin
overexpression is one of possible mechanism by which O. majorana
exerts its anti-invasive effect on the MDA-MB-231 cells.
Recent studies showed that treatment with histone deacetylase
inhibitors such as SAHA and trichostatin A strongly inhibited the migration
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and invasion of breast and prostate cancer cells and caused an
upregulation of E-cadherin [192, 193]. Histone Deacetylase (HDAC)
Inhibitors, promising anticancer agents, have been shown to mediate their
effects by activating the transcription of specific genes through histone
hyperacetylation. Interestingly, we have recently shown that O. majorana
induces hyperacetylation of Histone H3 and H4 at non-cytotoxic
concentrations. Moreover, O. majorana has been shown to contain
luteolin [98], a dietary flavonoid with Histone Deacetylase Inhibitor activity,
which was also shown to inhibit the invasive potential of MDA-MB-231
cells [188].
Based on these findings, we can suggest that one possible
mechanism by which O. majorana exerts its anti-migratory and antimetastatic effects on MDA-MB-231 involves an upregulation of E-cadherin
gene expression through Histone hyperacetylation. However, at this
stage, we cannot rule out the involvement of other mechanism(s) being
involved in this regulation. Further investigation will be needed to decipher
the exact mechanism by which O. majorana exert its effect on E-cadherin
expression.
The dissemination of cancer cells from the primary tumor is another
crucial event in the process of cancer invasion and metastasis, which
involves the degradation of the ECM and the components of the basement
membrane through proteases. Of these proteases, MMPs such as MMP2, MMP-9 and the uPA are thought to play a key role in cancer cell
invasion and metastasis [194, 195]. It has been shown that increasing
expression of MMPs in breast cancer cells correlates with increasing
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aggressiveness of breast cancer cell growth and metastatic potential
[196]. Therefore, inhibiting the activity or the expression of these
proteases can be considered as a potential therapeutic target against
breast cancer.

Interestingly, here we clearly demonstrate that O.

majorana exerts its anti-invasive affect against MDA-MB-231 cells by
significantly downregulating the expression of uPAR, MMP-2 and MMP-9
and decreasing the activity of these two proteases and consequently
reducing ECM degradation.
The ability of tumor cells to metastasize also largely depends on
their ability to adhere and transmigrate though endothelial cells. Cancer
cell-endothelial cell interaction is mediated by various adhesive molecules
such as intracellular adhesion molecule-1 (ICAM-1), vascular cell
adhesion molecule-1 (VCAM-1) and E- selectin [197]. Studies have shown
that the level of ICAM-1 protein expression on the cell surface positively
correlated with metastatic potential of several breast cancer cell lines [16].
Moreover, down regulation of ICAM-1 at the protein and mRNA levels
strongly inhibited human breast cancer cell invasion [16]. Tanshimone I, a
natural compound derived from medicinal plant, Salvia miltiorrhiza,
efficiently inhibited the adhesion of MDA-MB-231 cells to HUVECs by
down regulating the expression of ICAM-1 and VCAM-1 [198]. Recent
studies have revealed that ICAM-1 expression is associated with a more
aggressive breast tumor phenotype [199]. Based on these findings, ICAM1 represents a potential target in breast cancer treatment. Our study
revealed that O. majorana was able to reduce the expression levels of
ICAM-1 proteins in MDA-MB-231 cells and blocked their adhesion to the
645

human vascular endothelial cells (HUVECs).

Hence, we propose that

downregulation of ICAM-1 expression could be one mechanism by which
O. majorana blocks MDA-MB-231 cells capability to adhere to HUVECs
and consequently prevents their metastasis.
Angiogenesis, a process by which new blood vessels form, is
crucial for tumor growth and metastasis. Blockade of angiogenesis can
inhibit both tumor growth and metastasis [200]. Thus inhibition of
angiogenesis can be considered as a promising strategy in cancer therapy
[201, 202]. One possible way to block angiogenesis is to target proangiogenic factors secreted by tumor cells. VEGF is the major proangiogenic protein expressed in 60% of breast cancer patients at the time
of first diagnosis [203]. Interestingly, we found that O. majorana
significantly reduced the production of VEGF in both HUVECs and MDAMB-231 cells, suggesting that OME not only inhibits breast cancer cell
invasion, but could also block angiogenesis.
The NFB signaling pathway is known to regulate the expression of
various genes involved in the process of tumor metastasis. Elevated
levels of NFB are frequently detected in breast cancer cells. Studies
showed that inhibition of NFB activity could suppress metastasis in
breast cancer cells. In fact, studies showed that inactivation of NFB in
MDA-MB-231 breast cancer cells inhibit the expression of many
downstream target genes involved in tumor metastasis such as MMP-2
[196], MMP-9 [26, 204, 205], VEGF [205], ICAM-1 [26] and uPAR [26].
The phosphorylation of IB, by the IKKβ subunit of the IKK serine kinase
complex, is a crucial step in the activation of NFB.
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In fact, phosphorylation of IB triggers its polyubiquitination and
proteasome-mediated

degradation

with

consequent

NFB

nuclear

localization [206]. Nuclear NFB can then upregulate the transcription of
its target genes. Therefore, one way to inactivate the activated NFB
signaling in cancer cells is to block the phosphorylation of Ib by
inactivating the IKK complex. Interestingly, in the present work, we
demonstrated that O. majorana inhibited the phosphorylation of IB and
reduced the protein level of nuclear NFB suggesting that O. majorana
may negatively regulate the activity of NFB possibly by affecting the
activity of the IKK complex.

It is worth mentioning that O. majorana

significantly reduced the expression of several NFB downstream target
genes (MMP-2, MMP-9, uPAR, ICAM-1 and VEGF) involved in tumor
metastasis. It appears that the inhibitory effect on NFB could account for
the anti-metastatic effects of O. majorana.
Nitric Oxide (NO), synthesized by several nitric oxide synthases
(NOSs), nNOS/NOS-1, iNOS/NOS2 and eNOS/NOS3 is a signaling
molecule that regulates several physiological responses such as
vasodilatation, cell migration, immune reactions and apoptosis [198].
Interestingly, various studies have shown that NO can both promote and
inhibit tumor progression and metastasis. The pro- or anti-tumorigenic
activities of NO have been related to the p53 status [166, 207]. It has been
shown that NO-mediated apoptosis in leukemia cells requires wild-type
p53 [208]. On the other hand, it has been shown that iNOS/NOS2
expressing carcinoma cells with mutant p53 have accelerated tumor
growth and increased VEGF production [209]. NO was shown to promote
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cancer progression through the activation of oncogenic signaling
pathways including the extracellular signal-regulated kinases (ERK)1/2,
phosphoinositide 3-kinases (PI3K)/AKT, and c-Myc [124]. Recent studies
showed that increased iNOS/NOS2 and consequently NO production,
predicted poor survival in women with estrogen receptor α–negative (ERnegative) breast tumors. Moreover, exposure to NO enhanced cell motility
and invasion of Estrogen Receptor negative ER(-) cells [209]. It appears
then that discovery of inhibitors targeting NO production may be
particularly efficacious against ER(-), mutant p53 breast cancer patients.
In the present study we showed that O. majorana efficiently reduced the
level of NO production in the MDA-MB-231 in a concentration dependent
manner, suggesting that O. majorana might exert its anti-metastatic effect,
at least partly, by modulating the NO production in MDA-MB-231 cells. As
such, NO production may be an important target for chemoprevention
and therapy by O. majorana for the ER(-), mutant p53 MDA-MB-231 cells.
In summary, this study clearly demonstrated, for the first time, that
O. majorana possesses anti-invasive and anti-metastatic effects against
highly proliferative and highly invasive human MDA-MB-231 breast cancer
cell line by modulating the activity and/or the expression of proteins
regulating the process of cellular migration, adhesion invasion and
angiogenesis such as E-cadherin, ICAM-1, MMP-2, MMP-9, uPAR and
VEGF, at least partly, through inhibition of the NFB and NO signaling
pathways. Our results also showed that O. majorana inhibited tumor
growth and metastasis in an in vivo tumor growth assay. Thus, our current
study identifies Origanum majorana as a promising chemopreventive and
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therapeutic candidate that inhibits breast cancer growth and metastasis by
modulating the expression and activities of several targets. Nowadays,
there is a growing interest in combination therapy using multiple anticancer drugs affecting several targets/pathways, thus O. majorana
certainly merits a lot of attention and further exploration to identify novel
compounds for breast cancer therapy.
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GENERAL CONCLUSION
In conclusion, our study has focused on natural products such as
plant extracts and natural compounds found in nature and in our diets as
potential anti-breast cancer agents. We demonstrated that Salinomycin
induces apoptosis and senescence in breast cancer through upregulation
of

p21,

downregulation

of

survivin

and

Histone

H3

and

H4

hyperacetylation. Further, we provided evidence that Origanum majorana
attenuates breast cancer cell invasion, migration and tumor growth in vivo,
at least in part, through inhibiting the NF activation cascade and
reduction of Nitric Oxide production. In recent years, an increasing
number of natural products possessing anti-cancer properties have been
uncovered. Coupled with the elucidation of their anti-cancer mechanisms,
the exploitation of their use in clinical chemotherapeutic strategies is
promising. A potential advantage of phytochemicals and other compounds
derived from natural products is that they may act through multiple cell
signaling pathways and reduce the development of resistance by cancer
cells. Thus, natural products and naturally occurring phytochemicals are
indeed worthy of further development as anti-cancer and anti-metastatic
agents for clinical use.
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